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SUMMARY 
 
Sphingolipids are membrane components in eukaryotes, some prokaryotes and viruses. 
They play important roles in membrane structure, biological recognition and signal 
transduction (3-5). Serine palmitoyltransferase (SPT) catalyzes the first unique step of de 
novo sphingolipid biosynthesis, the condensation of serine and palmitoyl-CoA to form 
the sphingoid base backbone (6). We have studied the molecular and biological 
consequences of overexpression of SPT using HEK293 cells stably transfected with 
plasmids containing the cDNA for SPTLC1 and SPTLC2 (termed “SPT1/2 cells”). The 
effects of the elevated SPT activity were analyzed by measuring the sphingolipid 
amounts and types in these cells as well as by following the incorporation of [
13
C] 
palmitate into the sphingoid base (and/or fatty acid) backbones, which were analyzed by 
liquid chromatography, electrospray ionization-tandem mass spectrometry (LC-ESI-
MS/MS).  These studies revealed that most sphingolipid subspecies were elevated in 
SPT1/2 cells (with disproportionate increases in dihydrosphingolipids and subspecies 
with stearic acid in the ceramide backbone); however, sphingomyelins were lower.  The 
lower sphingomyelin does not appear to be caused by faster degradation, but possibly by 
substitution by dihydrosphingomyelins. Despite large increases in ceramide, a growth 
inhibitory and pro-apoptotic mediator in many cell types, the SPT1/2 cells did not display 
higher numbers of dead cells but, instead, grew faster than HEK293 cells.  Thus, 
increased de novo sphingolipid biosynthesis via this manipulation has uncovered several 
new features of this pathway that warrant further investigation. 
   
 xvi 
In the course of these studies, we noted by confocal microscopy that SPT1 is not only 
found in the endoplasmic reticulum, but also in the nucleus and focal adhesions.  This 
unexpected localization was confirmed in several cell lines, and by finding that SPT1 is 
co-immunoprecipitated with vinculin using an anti-vinculin antibody.  The association of 
SPT1 with focal adhesions may indicate that it plays a role in cell morphology and 
migration, and consistent with this hypothesis, focal adhesion staining of SPT1 is seen 
mainly before cells in culture reach confluence, and reappears when proliferation and 
migration is reinitiated by a standard scratch-wound healing assay.  Furthermore, 
elimination of SPT1 using SPTLC1 siRNA causes cell rounding that does not appear to 
be due to interference with de novo sphingolipid biosynthesis.  Thus, in addition to its 
“traditional” role in de novo sphingolipid biosynthesis in the ER, SPT1 is present in other 
cellular compartments and is required for normal cell morphology and migration.  
 
 SPT1 was hypothesized to be present in cells in more than one isoform 
because GenBank has at least three putative SPT1 transcipts that can be rationalized 
to be produced by alternative splicing. The predicted amino acid sequence of one 
isoform (which we term SPTLC1L) is longer than the SPT1 that has heretofore been 
associated with SPT activity, and this isoform appears to be expressed in Hek cells 
because a polypeptide of the predicted size was found by antibodies against its 
unique amino acid sequence.  The functions of the alternative isoforms are not yet 
clear; however, their existence futher underscores how much remains to be learned 
about the biochemistry and regulation this pathway and its components. 
  
1 
CHAPTER 1 
Review of Serine Palmitoyltransferase  
 
1.1 Sphingolipid  
 
1.1.1 Structure and de novo synthesis of sphingolipid molecules 
 
Sphingolipids are a family of phospholipids and glycolipids built upon sphingoid base 
backbones. There are three major types of sphingoid bases, sphingosine (So), sphinganine 
(Sa, dihydrosphingosine) and phytosphingosine (4-hydroxydihydrosphingosine). The 
majority of the sphingoid bases in cells are N-acylated with long-chain fatty acids to 
produce ceramides (Cer) (Fig. 1.1). By adding a head group at 1-hydroxy position 
ceramide can be converted to sphingomyelin (SM) or ceramide monohexoside (CMH) 
including glucosylceramide (GluCer) and galactosylceramide (GalCer). CMH would be 
converted to various glycosphingolipids (GSL) by adding more carbohydrate groups. 
 
 
 
 
 
 
 
 
Figure 1.1 Structure of sphingolipid molecules (1) 
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Intracellular sphingolipids are from extracellular uptake, de novo synthesis and turnover 
from complex sphingolipids. The capacity for de novo sphingolipid biosynthesis (Fig. 1.2) 
is widespread among cell types and tissues (2). The pathway starts from condensation of 
serine and palmitoyl-CoA by SPT to form 3-keto-sphinganine (3-keto-Sa) which is 
quickly converted to Sa by 3-keto-sphinganine reductase. The desaturated form of Sa is 
So and both of them can be phosphorylated to form sphinganine-1-phosphate (Sa1P) and 
sphingosine (S1P) which are bioactive signaling molecules. Unlike Sa, So is only derived 
from turnover of ceramide. Both Sa and So can be N-acylated by (dihydro)ceramide 
synthase (CerS) to form dihydro-ceramide (DHCer) and Cer sequentially. Then DHCer 
and Cer are further converted to more complex Sphingolipids (DHSM, DHCMH, SM, 
CMH etc.) by adding different head groups.   
  
In the absence of an exogenous sphingoid base source, loss of this pathway by mutation
 
of SPT or its inhibition by ISP1/myriocin or sphingofungin
 
B affects growth and viability. 
It is intriguing that this pathway contains so many compounds, which affect cell behavior 
when added exogenously or formed via
 
sphingolipid turnover, that the consequences can 
be growth
 
arrest and cytotoxicity or growth stimulation
 
or inhibition of apoptosis.
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1.1.2 Functions of sphingolipids  
 
Most sphingolipids (SM, GSL) are membrane constituents and found in different 
subcellular compartments but some are present in biological fluids. So has a role in 
regulating the cell cycle and apoptosis (7). Ceramide mediates many cell-stress responses, 
Fig. 1.2 De novo biosynthetic pathway for sphingoid bases and complex sphingolipids 
(2). The color coding distinguishes the biosynthetic enzymes (with common names in red 
and green arrows for the reactions catalyzed) and intermediates (in blue) from additional 
reactions that occur with these intermediates (in black). The dashed line for (N-
acyl)phytosphingosine synthesis reflects that in yeast, where this has been best 
characterized. 
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including the regulation of apoptosis (8), cell senescence (9), and autophagy (10), 
whereas S1P has crucial roles in cell survival, cell migration and inflammation (11). 
Complex sphingolipids (glycosphingolipids and sphingomyelins) affect cell behavior by 
associating with membrane microdomains that contain receptors, transporters, and other 
signal transducers such as Src family kinases, small G-proteins (e.g., RhoA, Ras), and 
focal adhesion kinase (12, 13). The above is not a complete list of sphingolipid functions 
and the implications of sphingolipids in biological processes are discovered more and 
more every year.  
 
1.2 Biochemical and genetic characteristics of SPT   
 
1.2.1 Early history of SPT 
 
Following over a decade of speculation about how serine and palmitic acid might serve as 
the precursors for the sphingoid base backbones of sphingolipids, Braun and Snell (14) 
and Stoffel et al. (15) demonstrated that serine and palmitoyl-CoA could be condensed to 
form 3-keto-Sa that was rapidly reduced to Sa if NADPH was also present, thereby 
establishing the first steps of the de novo biosynthetic pathway for sphingolipids.  In 
subsequent decades, some of the properties of SPT were elucidated (16), such as a 
requirement for pyridoxal 5’-phosphate, a predominate localization of SPT activity in the 
endoplasmic reticulum (ER), the apparent kinetic properties, and various aspects of its 
regulation; however, the difficulty of purifying this membrane-associated enzyme until 
relatively recently (17) and the lack of knowledge about its gene(s) was a serious 
impediment to progress. 
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1.2.2 Genes of serine palmitoyltransferase (SPT)  
 
Sphingolipid biosynthesis is initiated by condensation of L-serine with palmitoyl-CoA by 
serine palmitoyltransferase (SPT); therefore, this is a critical enzyme for this pathway.  
In mammalian cells, SPT is thought to be a membrane bound heterodimer comprised of 
two subunits, SPT1 and SPT2, with molecular weights of 53 kDa and 63 kDa, 
respectively (17, 18), but recently, an additional subunit, SPT3, has also been found in 
some cells and tissues (19). In the early 1990’s, Lester, Dickson, and their co-workers 
isolated mutant strains of S. cerevisiae that require an external supply of 
phytosphingosine for growth and for the synthesis of complex sphingolipids, and showed 
that the mutant strains are defective in SPT activity (20). Mutations that caused complete 
loss of SPT activity were shown to fall into two genetic complementation groups, Lcb1 
and Lcb2, and their wild-type alleles (LCB1 and LCB2) were isolated by functional 
rescue experiments (20-22).  With the availability of the yeast genes for SPT, 
identification of the mammalian homologs soon followed for human, mouse, and CHO 
cells (23-25). There is ~40% identity between yeast and mammalian SPT proteins, and 
~95% identity among the mammalian proteins.  As for many genes, the nomenclature for 
the mammalian SPT genes initially followed that of the microbial genes (e.g., LCB) but 
was later renamed SPTLC for the human genomic homologs of the yeast LCB genes 
respectively).   
 
In the human genome, SPTLC1 comprises 15 exons spanning ~85 kbp on chromosome 
9q21-q22 region; SPTLC2 comprises 12 exons spanning ~110 kbp on chromosome 
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14q24.3-q31 region and SPTLC3 is composed of 12 exons on chromosome 20 p12.1–
12.3.  The predicted MW of human SPT1, SPT2 and SPT3 are 53 kDa, 63 kDa and 
63kDa, respectively, and polypeptides of this approximate size are seen on Western blots 
of human and mouse cells using protein specific antibodies (17, 19, 23).  The SPT1 and 
SPT2 subunits have ~20% identity and have a single highly hydrophobic domain in the 
amino-terminal region, which probably represents a transmembrane domain without 
cleavable signal sequences (23, 24). SPT3 subunit has an identity to SPT2 subunit of 68%.    
 
1.3 SPT-associated proteins  
 
Dunn and co-workers have shown that an additional 10-kDa peptide, the product of the 
Tsc3 gene, is associated with the SPT1/SPT2 complex in the yeast S. cerevisiae (26).  
Tsc3p is not essential for activity, but is required for optimum activity of SPT in yeast.  
No mammalian homolog of Tsc3 has been found so far even by computer search of 
sequence databases or upon affinity purification of SPT from CHO cells (17).  Inuzuka et 
al.(27) described a class of endoplasmic proteins (termed Serinc1 to 5) in yeast and 
mammalian cells that increase the synthesis of both phosphatidylserine and sphingolipids.  
Overexpression of Serinc1 in COS cells doubled SPT activity, therefore, Serinc may 
interact with SPT to facilitate serine utilization.    
 
Using proteomic technologies (tandem-affinity purification and mass spectrometry) to 
discover protein-protein interactions, a substantial number of proteins have been 
identified as potential LCB2-associated proteins in Saccharomyces cerevisiae (28).  
These proteins are involved in various biological processes such as vesicle transport, 
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nuclear import and export, among others.  A genome-wide yeast two-hybrid analysis in 
Drosophila (29) has suggested that SPT2 may interact with 13 proteins, which include a 
proton transporter, organic cation transporter, hsc-70, and ribosomal proteins, among 
others. 
 
1.4 Structure and mechanism of the SPT reaction 
 
SPT has significant structural and mechanistic similarities to members of a subfamily of 
PLP-dependent enzymes that includes 5-aminolevulinic acid synthase, 2-amino-3-
ketobutyrate ligase, and 8-amino-7-oxononanoate synthase.  These enzymes catalyze 
condensation of amino acids and the CoA thioesters of carboxylic acids to produce α-
oxoamines, therefore, have been referred to as the PLP-dependent α-oxoamine synthase 
(POAS) family.  However, the eukaryotic SPT’s are the only members of this family that 
have been identified to date to be membrane bound and heterodimeric--all other members 
are soluble homodimers.  In contrast to eukaryotic SPT, Sphingomonas paucimobilis 
produces a soluble SPT that is ~30% identical to both mammalian SPT1 and SPT2 at the 
amino acid level, but is a homodimer of a 45-kDa protein (30). POAS members share a 
conserved motif around the lysine that is responsible for formation of a Schiff’s base with 
pyridoxal 5’-phosphate (PLP)(T[FL][GTS]K[SAG][FLV]G).  This motif is present in 
SPT2 and SPT3 and not in SPT1. PLP is moderately tightly bound by SPT with an 
apparent Km of approximately 0.1 µM for the mammalian enzyme (31). 
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It has long been noted (32) that the involvement of PLP in removing the carboxyl group 
of serine during the condensation of serine and palmitoyl-CoA allows two mechanisms to 
be postulated:  formation of PLP-stabilized carbanion by decarboxylation of the substrate 
L-serine, followed by acylation, or formation of a carbanion by removing the α-hydrogen 
atom of L-serine, followed by acylation and decarboxylation (shown in Fig. 1). 
Krisnangkura and Sweeley (33) provided strong evidence for the latter mechanism by 
demonstrating that the α-hydrogen atom of serine is replaced by a proton from H2O 
during the reaction, which has also been found for the condensation reactions catalyzed 
by 5-aminolevulinic acid synthase (34) and other enzymes of this family. In addition, the 
structures of several potent SPT inhibitors (i.e., sphingofungins and myriocin) resemble 
that for a potential transient state intermediate with the carboxyl group of L-serine still 
present, which would be found in latter pathway (as shown in the insert in Fig. 1). 
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1.4.1 Substrate selectivity of SPT 
 
1.4.1 Substrate selectivity of SPT 
 
SPT strictly utilizes l-serine as its amino acid substrate; however, D-serine is a 
competitive inhibitor with an IC50 of ~0.3 mM, which is similar to the Km for l-serine 
(17).  SPT is also highly selective for the co-substrate fatty acyl-CoA with the 
mammalian enzyme (17, 31) utilizing palmitoyl-CoA (C16:0) > pentadecanoyl- and 
heptadecanoyl- CoA’s (C15:0 and C17:0) >> stearoyl-CoA (C18:0) and essentially no 
unsaturated species except palmitelaidic acid (t16:1), which has an uncommon trans- 
versus cis- double bond.  This selectivity, combined with the abundance of palmitoyl-
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Fig. 1.3  Suggested catalytic pathway of serine palmitoyltransferase (SPT) and rationale 
for inhibition by myriocin-like compounds (insert)   
Starting with the internal aldimine of pyridoxal 5’-phosphate (PLP) with an active site lysine 
(I), Serine is bound by SPT as an external PLP aldimine (II), deprotonated at the α-carbon and 
condensed with palmitoyl-CoA (III) (possibly through this quinonoid intermediate), followed 
by decarboxylation of the doubly β,γ-unsaturated intermediate IV, proton abstraction (V) and 
release of the produce 3-ketosphinganine (VI).  The insert illustrates the similarities between 
the presumed aldimine of myriocin with SPT and catalytic intermediate IV. 
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CoA (and scarcity of C15:0 and C17:0 fatty acids in most species except ruminants) 
probably accounts for the extremely high 18-carbon-chain-length specificity of most 
sphingoid bases in mammalian sphingolipids.  Indeed, in species where other chain 
lengths are found, such as Drosophila which contain 14-carbon sphingoid bases, or 
Sphingomonas which displays very little sphingoid base specificity, this is reflected in 
differences in the fatty acyl-CoA selectivity of the SPT from these species (35, 36).  A 
question that remains to be answered is why atypically long sphingoid bases (with 20-
carbon atoms) are found in mammalian gangliosides (1, 37) and especially in 
hippocampus (38); otherwise, these types of sphingoid bases have mainly been observed 
in yeast under certain stages of growth and stress, and are thought to have roles in cell 
signaling (39).   
 
These kinetic properties of mammalian SPT, which were measured in vitro and are 
subject to numerous complications inherent in assaying lipid metabolizing enzymes under 
artificial conditions, have nonetheless been closely replicated in studies of intact LM cells 
(40) and hepatocytes (41) where the cellular concentrations of serine and palmitate were 
varied.  Physiologic concentrations of serine are known to fluctuate above and below the 
Km for SPT (40), which might interfere with sphingolipid metabolism and explain why 
cells have the recently discovered Serinc (for serine incorporating) proteins to facilitate 
utilization of this precursor (27).  It has also been noted (42) that since D-serine is a 
strong competitive inhibitor for L-serine, and substantial quantities of D-serine are 
present in discrete areas of the brain and some other tissues, D-serine might affect de 
novo sphingolipid synthesis in these cells (also providing, perhaps, one of the rationales 
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for the Serinc proteins).  Indeed, serine homeostasis is itself highly complex and part of 
the one-carbon-metabolism system that includes the biosynthesis and turnover of glycine 
and methionine, methylation of proteins, lipids and nucleic acids, and many other 
important regulatory pathways.  Recently it was found that alanine could be used as an 
SPT substrate to form 1-deoxysphinganine (1-deoxy-Sa) in fumonisin B1 treated cells 
suggesting that under certain circumstances SPT might not strictly require serine as its 
substrate in vivo (43). The mechanism for SPT substrate selection is not clear yet. These 
issues illustrate the fundamental questions that have not yet been answered about how de 
novo sphingoid base biosynthesis is coordinated with other metabolic pathways, which 
one hopes is at last becoming feasible to address with the types of systems models that 
have been developed for the metabolic pathway in yeast (44-46). 
 
1.4.2 Inhibitors of SPT 
 
A fairly high number of naturally occurring inhibitors of SPT have been discovered and 
many can be rationalized due to their structural similarity to reaction intermediates, such 
as myriocin shown in the insert of Fig. 1. These include sphingofungins, lipoxamycin 
(neoenactin M1), myriocin (ISP-1/thermozymocidin) and sulfamisterin, which are potent 
(i.e., with IC50 in the nanomolar range) and, as far as has been determined to date, high 
selective for fungal and mammalian SPT (47-50).  Viridiofungins (51) are also potent 
inhibitors of mammalian SPT, but also inhibit squalene synthase.  As expected for an 
enzyme that utilizes pyridoxal 5’-phosphate, SPT is also inhibited by compounds such as 
l-Cycloserine and β-chloro-l-alanine in intact cells, however, this is usually not desirable 
because these compounds affect too many other metabolic pathways as well.  
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1.4.3 Kinetic and spectroscopic studies of the mechanism of SPT 
 
Because the SPT from Sphingomonas paucimobilis is a soluble homodimer (30), it has 
been much more extensively characterized than the membrane-bound SPT’s (35, 52). The 
purified recombinant SPT has an absorption spectrum with maxima at 426 and 338 nm, 
which was interpreted as the aldimine (species “I” in Fig. 1) and enolimine tautomer, 
respectively, of PLP with the active site lysine.  Ikushiro et al. also reported that addition 
of L-serine caused an increase in 426 nm absorption indicative of formation of the 
external aldimine intermediate (species “II”), however, absorption at ~500 nm was not 
detected by rapid mixing or static methods, which suggests that the quinonoid 
intermediate (species “III”) does not accumulate.  As noted by these authors, this does not 
necessarily preclude the existence of intermediate “III”, but it may not form until addition 
of palmitoyl-CoA.  The absorption and CD spectra of the SPT-myriocin complex were 
also consistent with the formation of an external aldimine, as hypothesized in Fig. 1.  
Interestingly, addition of sphinganine or sphingosine also altered the spectrum, although 
in-depth studies were precluded by the low solubility of these compounds.  This may 
indicate that interaction between SPT and its product (and/or downstream products) 
might affect activity. 
 
1.5 Regulation of SPT 
 
SPT activity and mRNA have been found in very mammalian tissue and cell type and are 
especially abundant in organs such as kidney, lung and liver (23, 53).  In addition, SPT 
activity depends on the developmental stage of tissues (54) and is affected by 
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environmental factors such as diet in several tissues (55, 56).  Although surprisingly little 
is known about SPT regulation—and SPT is sometimes erroneously referred to as a 
“housekeeping enzyme”, a growing number of animal studies and investigations with 
cells in culture are documenting transcriptional and post-transcriptional regulation of SPT 
activity. 
 
1.5.1 Transcriptional and post-transcriptional regulation in response to 
extracellular stimuli  
 
Many of the factors that have been reported to increase SPT mRNA and activity are 
summarized in Table 1.  A large fraction of the stimuli are inflammatory, toxic or some 
other form of stress.  Intraperitoneal administration of endotoxin to Syrian hamsters 
increased SPT activity 2- to 3-fold in the liver, spleen, and kidney with a concomitant 
increase in SPT2/LCB2 mRNA (57).  Similar changes were observed upon administration 
of interleukin 1ß (IL-1), an inflammatory cytokine.  Irradiation of keratinocytes with 
ultraviolet A (UVA) upregulated SPT activity as well as mRNA (58); ultraviolet light B 
(UVB) also affects SPT mRNA in epidermal cells (59).  SPT activity in epidermal cells 
appears to be up-regulated in response to barrier requirements of skin (60).  These results, 
along with the observation that inflammation and UVB stimuli also enhance the synthesis 
of other lipid types, including fatty acids and cholesterol (61, 62), raises the possibility 
that a lipogenic signaling pathway(s) is involved in transcriptional control of SPT genes.  
Consistent with this possibility, both SPT1 and SPT2 mRNA are increased when cultured 
human keratinocytes are treated with nicotinamide, which also enhances fatty acid and 
cholesterol synthesis (63).  The expression of SPT1 mRNA is also up-regulated in islets 
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of leptin-receptor-deficient obese fa/fa rats, compared to the levels in control islets, and 
this up-regulation is suggested to be a response to an increase in intracellular fatty acid 
(64). A recent study showed that high fat diet led to a substantial increase of SPT in vitro 
activity and the SPT1 protein amount in ldlr-/- mice (65).  
 
Cytotoxic accumulation of palmitate induces apoptosis accompanied by an elevation of 
the intracellular ceramide level in various cell types, including the hematopoietic LyD9 
cell line, fa/fa pancreas islets, astrocytes, and CHO cells (66).  For most cell types, 
enhanced de novo synthesis of ceramide via SPT is required for palmitate-induced 
apoptosis (64, 66-68), whereas palmitate-induced apoptosis of CHO cells is suggested to 
occur through a ceramide-independent, but reactive oxygen species-dependent, pathway 
(67).  Palmitate-induced enhancement of SPT activity in primary astrocytes is prevented 
by exposure of cells to an activator of AMP-activated protein kinase (AMPK) (68).  The 
AMPK cascade acts as a metabolic sensor that monitors cellular AMP and ATP levels, 
and once activated, down-regulates various ATP-consuming anabolic pathways including 
fatty acid and cholesterol synthesis.  The AMPK cascade might also participate in the 
regulation of sphingolipid synthesis. 
 
Certain types of apoptotic stimuli appear to increase SPT activity with little or no change 
in mRNA amount, hence, may act post-transcriptionally (Table 1).  Upon treatment with 
retinoic acid, mouse teratocarcinoma PCC7-Mz1 cells undergo apoptosis, but a fraction 
begins to differentiate in a manner mimicking the early steps of neuronal development.  
Retinoic acid treatment of PCC7-Mz1 stem cells induces accumulation of ceramide 
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accompanied by an increase in SPT activity without any increases in SPT1 and SPT2 
mRNA (69).  Likewise, treatment of Molt-4 human leukemia cells with the chemotherapy 
agent etoposide elevates both SPT activity and intracellular ceramide without increasing 
SPT mRNA (70). During cannabinoid-induced apoptosis, both SPT activity and 
intracellular ceramide increase 4 to 6 fold without major changes in SPT mRNA or 
protein in a subline of the rat glioma C6 cells. When these cells have been treated also 
with inhibitors of de novo sphingolipid synthesis to block the increase in ceramide, there 
is usually also a decrease in apoptosis in response to these stimuli (69, 70) which suggests 
that the elevation in ceramide is a mediator of, rather than merely a consequence of, the 
pro-apoptotic effects of these agents. De novo sphingolipid biosynthesis (and SPT 
activity) is also rapidly up-regulated in Molt-4 cells during heat shock (71), and heat 
shock is well known to affect—and to be influenced by--sphingolipid biosynthesis in 
yeast (72). 
 
1.5.2 Regulation of SPT for homeostasis of cellular sphingolipid amounts 
 
Little is known about what controls the sphingolipid amounts of cells.  A plausible 
feedback regulator is sphingosine (or perhaps sphinganine) 1-phosphate because addition 
of sphingosine or an analog that accumulates in the cells as the phosphate metabolite to 
cultured mouse cerebellum cells significantly decreases SPT activity (which does not 
appear to be due to direct inhibition of SPT by the sphingoid base because SPT activity is 
not reduced when microsomes are incubated directly with sphingoid bases) (73, 74). 
Similarly, accumulation of S1P and Sa1P by treating primary cultured cerebellum 
neurons with high concentrations of a dihydroceramide desaturase inhibitor, GT11, 
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reduced SPT activity by about 90% without changing SPT mRNA amount, which could 
reflect feedback inhibition of SPT (75).   Puzzlingly, depression of de novo sphingolipid 
synthesis by exogenous ceramide or its analogs seems not to be accompanied by any 
inhibition of the activities of anabolic enzymes, including SPT (76, 77). It is clear that 
more studies are required to elucidate the mechanisms underlying the regulation of cell 
sphingolipid homeostasis via de novo synthesis versus recycling of endogenous and 
exogenous sphingoid bases.  
 
 
mRNA (protein) Stimulus or condition 
(tissue or cell type) 
Activity 
 SPTLC1
/LCB1 
SPTLC2
/LCB2 
References 
UVB  
(mouse epidermis and cultured human 
keratinocytes) 
1.5 1.5
a
 2-3
a 
(2) 
(59, 62) 
UVA 
(human keratinocytes) 
2.5 14 7 (58) 
Endotoxin, IL1 
(liver, spleen and kidney of Syrian 
hamster) 
2-3 nd 2-4 (57, 78) 
Endotoxin, IL1, tumour necrosis 
factor-α 
(human HepG cell line) 
2-3 nd 2-3 (57) 
Leptin receptor mutation 
(rat pancreas islet) 
nd
b
 2-3 nd (64) 
Fatty acids 
(rat pancreas islet) 
nd
b
 1.5-2 nd (64) 
Palmitic acid 
(rat astrocytes) 
1.3 nd nd 
(1.4) 
(68) 
Nicotineamide 
(cultured human keratinocytes) 
1.2 1.8 1.8 (63) 
Etoposide 
(human leukemia Molt-4 cell line) 
2-3 – – (70) 
     
Table 1.1 Stimuli/conditions that up-regulate SPT activity in mammalian cells 
 
–, no increase; nd, not determined 
a
After stimulation, the levels initially decreased by ~50%, but subsequently increased 
above unstimulated control levels. 
b
De novo sphingolipid synthesis in intact cells was significantly increased. 
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Table 1.1 continued 
Retinoic acid 
(mouse teratocarcinoma PCC7-Mz1 
cell line) 
3 – – (69) 
Resveratrol  
(human breast cancer cells) 
1.5 – – (79) 
D
9
-Tetrahydrocannabinol 
(a subline of the rat glioma C6 line) 
6 1.4 
(1.8) 
1.1 (80) 
Activation of angiotensin II type 2 
receptor 
(a subline of the rat 
pheochromocytoma PC12 cell line) 
2 nd nd (81) 
N-(4-hydroxyphenyl)retinamide 
(human neuroblastoma CHLA-90 cell 
line) 
2 nd nd (82) 
Hexachlorobenzene  
(rat liver) 
1.5-2
a
 nd nd (83) 
Apolipoprotein E knockout 
(mouse liver) 
2 nd – (84) 
 
 
1.6 Significance of studying SPT and sphingolipid de novo synthesis  
 
1.6.1  SPT is essential for survival 
 
In addition to being essential for yeast (20), SPT activity (or exogenous addition of 
sphingoid bases) has been shown to be required for survival of a temperature-sensitive 
Chinese hamster ovary (CHO) cell mutant (strain SPB-1) with a thermolabile SPT was 
isolated after selection by in situ colony assay (85).  Knockout of SPT in fruit flies results 
in embryonic lethality (86), whereas when the SPT deficiency is partial, mutant flies 
grow into adults with abnormalities which can be rescued by feeding with sphingosine. 
Attempts to produce homozygous knockout mice were also unsuccessful due to 
embryonic lethality (87), although heterozygotes were healthy and had lower SPT mRNA, 
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protein, and activity in some tissues (e.g., liver).  Thus, all of the studies to date 
demonstrate that sphingolipids are essential for survival of the organisms in which they 
are produced (i.e., from fungi to invertebrates and mammals). 
 
1.6.2 SPT in hereditary sensory neuropathy type I (HSN1) 
 
HSN1 is a dominantly inherited disease involving the progressive degeneration of lower 
limb sensory and autonomic neurons.  HSN1 is a genetically heterogeneous disease, and 
at least three gene variants are reported.  It has recently been revealed that the genetic 
defect in the HSN1 families linked to the chromosome 9q22 locus is associated with 
missense mutations in the human SPTLC1 gene, which alter a specific amino acid residue 
(Cys133 or Val144) in the SPT1 subunit. 
 
Expression of SPT1/LCB1 mutants having the HSN1 mutations has been shown to inhibit 
SPT activity and sphingolipid synthesis in CHO cells and yeast.  The mutated SPT1 
proteins remained capable of forming a complex with the SPT2 subunit, but the complex 
was enzymatically inactive, which suggests that the mutant SPT1 may have a dominant 
negative-like phenotype.  However, the consequences of the mutations may be more 
complex because despite the reduction in SPT activity, the rates of sphingolipid 
biosynthesis, cell proliferation, and death in HSN1 cells were not changed (88).    
The amino acid sequence around Cys133 and Val144 in SPT1/LCB1 is highly conserved 
from yeast to mammals.  Although the crystallographic analysis of a mammalian SPT has 
not been conducted, the tertiary structures of other enzymes in this family reveals that the 
catalytic site is formed at the interface between the subunits, hence, both Cys133 and 
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Val144 of SPT1 are predicted to be spatially close to the PLP-binding site of SPT2.  
Presumably, the amino acid sequence around Cys133 and Val144 in SPT1 is involved in 
the formation of the catalytic site, and the HSN1 mutant types of SPT1 are unable to 
contribute to the formation of the active catalytic site.  It remains unclear why mutations 
in a protein widely expressed in all tissues trigger pathology that is highly restricted to 
specific subsets of cells within a tissue. 
 
1.6.3  Roles of SPT in other biological processes and diseases 
 
SPT is the initial enzyme of a complex metabolic pathway that produces thousands, and 
potentially tens of thousands, of different molecular species of sphingolipids.  While the 
endproduct complex sphingolipids are known--or in most cases presumed on teleologic 
grounds--to have cell functions, the turnover products (e.g., ceramide) and biosynthetic 
intermediates (e.g., sphinganine) have also been shown to be highly bioactive and to 
participate in both the etiology and sometimes suppression/treatment of disease.  Hence, 
SPT is an interesting candidate as a drug target. Recent experiments showed that SPT 
activity increased along with development stages of rat brains and declined in hypoxic-
ischemic brains, which suggests that SPT plays an important role in neuro system 
myelination (89). Some existing drugs have already been suggested to act at least in part 
via increasing SPT activity.  N-(4-Hydroxyphenyl)retinamide (4HPR or fenretinide) is a 
chemotherapy drug undergoing human clinical trials. At first, it was reported to elevate 
ceramide in numerous human cancer cell lines (90, 91) by coordinate activation of SPT 
and (dihydro)ceramide synthase (82). Most recently, it was found that sphinganine and 
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dihydroceramide but not ceramide were elevated in 4HPR treated cancer cells (92). The 
anti-proliferative effect of a selective COX-2 inhibitor, celecoxib, is through increasing 
de novo synthesis of sphinganine and dihydroceramide (DHCer) (93). A dietary factor, 
resveratrol, is antiproliferative and proapoptotic, and its effects correlate with an increase 
in endogenous ceramide that has been suggested to involve activation of SPT and neutral 
sphingomyelinase (79). In Molt-4 human leukemia cells, the chemotherapy agent 
etoposide increases ceramide due to upregulation of SPT activity (70). γ-Tocopherol, the 
predominant form of vitamin E in diets, induces apoptosis of LNCap cells and addition of 
myriocin to inhibit SPT protects cells from γ-tocopherol–induced apoptosis (94).  
Increases in ceramide have also been proposed to mediate the tamoxifen-dependent 
accumulation of autophagic vacuoles in MCF-7 cells (95) . 
  
Investigators have for several decades contemplated provocative associations between 
sphingolipid metabolism and atherosclerosis, however, recent studies of atherosclerotic 
lesion development in apoE-deficient mice have provided a link between SPT inhibition 
and this disease.  Hojjati et al. have reported that treatment of apoE-deficient mice with 
myriocin decreases plasma sphingomyelin, ceramide, and sphingosine-1-phosphate and 
reduces atherosclerotic lesion area (96). Manipulation of de novo sphingolipid 
biosynthesis may have benefits for multiple pathologies associated with advanced age 
because a link is also surfacing between sphingolipids, lipid rafts, and their components 
(cholesterol) in the processing of β–amyloid precursor protein (APP).  The secretion of 
soluble APPα and generation of C-terminal fragment cleaved at α-site dramatically 
increased via activation of MAPK/ERK pathway in Chinese hamster ovary cells treated 
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with myriocin and in a mutant, LY-B strain defective in the SPT1 protein (97). This 
indicates modulation of sphingolipid metabolism may able to influence the pathogenesis 
of Alzheimer’s disease by affecting APP cleavage.  These examples actually highlight 
just a few of the promising indications that SPT is a potential pharmaceutical target for 
prevention and treatment of disease.   
 
1.7 Objectives of the study 
 
The main goal of this work is to study the classic and novel functions of SPT. If SPT 
activity is increased by overexpression of SPT1 and SPT2 subunits what are the 
molecular and biological consequences of it. We also want to know the subcellular 
localizations of endogenous SPT and if SPT play the same role in the different locations. 
It is also our interest to know if SPT isoforms exist and if they are responsible for the 
synthesis of sphingoid bases with different chain lengths.  
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CHAPTER 2 
Consequences of increasing the expression of SPT in a cell model system 
 
2.1 Introduction 
 
SPTLC genes have been expressed in mammalian cell lines before (18, 23). However, 
because of method limitation its molecular consequences and the effect on de novo 
synthesis of sphingolipids have not been evaluated. Previous study showed that HEK293 
cells express SPTLC1 and SPTLC2 but not SPTLC3 (19). HEK293 cells stably expressing 
SPTLC1 and SPTLC2 (SPT1/2 cells) were generated and used for our study. A method 
for quantification of sphingolipid de novo synthesis has been developed by our lab. 
Uniformly labeled [
13
C] palmitate was used to label the sphingoid base backbone and 
fatty acid (including longer chain fatty acids by elongation of the [
13
C] palmitate) 
followed by LC ESI-MS/MS analysis. Using this method, the de novo synthesis of 
sphingolipid was compared in SPT1/2 cells and HEK293 cells and sphingolipid amount 
was not only quantified for each sphingolipid species but also for each of its subspecies 
with different fatty acyl chain lengths. Our analyses confirmed that overexpression of 
SPTLC1 and SPTLC2 in HEK293 cells increased the flux through the de novo pathway 
and most de novo species were elevated except for sphingomyelin. The subspecies with 
various chain lengths were quantified and among them C18 subspecies has the highest 
fold elevation in SPT1/2 cells. Newly synthesized sphingolipids that have very low 
amount in HEK293 cells, such as Sa, 1-deoxySa and dihydro-species, are highly elevated 
in SPT1/2 cells.     
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2.2 Materials and methods 
 
2.2.1 Materials 
 
The HEK293 cells were obtained from the American Type Culture Collection (Manassas, 
VA).  All tissue culture plastic ware was obtained from Corning (Corning, NY). Fetal  
bovine serum was supplied by Hyclone (Logan, Utah). The affinity purified polyclonal 
rabbit anti-human primary antibodies raised against SPT1 peptides have been previously 
described (98). The epitope sequences that were used to generate the antibody are 
“KLQERSDLTVKEKEE” (aa 45-59) and “EQEIEDQKNPRKAR” (aa 223-236). C6-
NBD-SM and C6-NBD-Cer are from Avanti Polar Lipids (Alabaster, AL). Protease 
inhibitor cocktail was obtained from Roche (Indianapolis, IN). The internal standard 
cocktail (catalog number LM-6002) was provided by Avanti Polar Lipids (Alabaster, AL) 
in sealed ampoules and certified (99) to be > 95% pure and within 10% of the specified 
amount (250 µM); it was comprised of  the 17-carbon chain length sphingoid base 
analogs:  C17-sphingosine, (2S,3R,4E)-2-aminoheptadec-4-ene-1,3-diol (d17:1-So); C17-
sphinganine, (2S,3R)-2-aminoheptadecane-1,3-diol (d17:0-Sa); C17-sphingosine 1-
phosphate, heptadecasphing-4-enine-1-phosphate (d17:1-S1P); and C17-sphinganine 1-
phosphate, heptadecasphinganine-1-phosphate (d17:0-Sa1P); and the C12-fatty acid 
analogs of the more complex sphingolipids C12-Cer, N-(dodecanoyl)-sphing-4-enine 
(d18:1/C12:0-Cer); C12-Cer 1-phosphate, N-(dodecanoyl)-sphing-4-enine-1-phosphate 
(d18:1/C12:0-Cer1P); C12-sphingomyelin, N-(dodecanoyl)-sphing-4-enine-1-
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phosphocholine (d18:1/C12:0-SM); C12-glucosylceramide, N-(dodecanoyl)-1-β-
glucosyl-sphing-4-eine (d18:1/C12:0-GlcCer); and C12-lactosylceramide, N-
(dodecanoyl)1-β-lactosyl-sphing-4-eine (d18:1/C12:0-LacCer); as well as one very-long-
chain Cer analog, C25-Cer, N-(pentacosanoyl)-sphing-4-enine (d18:1/C25:0-Cer).  U-
[
13
C]-palmitate (98%) was purchased from Cambridge Isotope (Andover, MA). The 
HPLC grade solvents (acetonitrile, # EM-AX0145; chloroform, # EM-CX1050; hexane, 
# JT9304-33; and methanol, # EM-MX0475, as well as formic acid (ACS grade, # EM-
FX0440-7), were obtained from VWR (West Chester, PA), and acetic acid (ACS grade, # 
A38C-212) was obtained from Fischer (Pittsburg, PA). 
 
2.2.2 Cell culture  
 
HEK293 cells and SPT1/2 cells were grown in DMEM / F12 medium (1:1) (Gibco BRL, 
MD) supplemented with 10 % fetal bovine serum (FBS), penicillin (100 U / ml) and 
streptomycin (100 µg /ml) at 37 °C in a humidified 5 % CO2 atmosphere.  
 
2.2.3 Generation of SPT1 and SPT2 over-expressing cell lines 
 
SPTLC1 and SPTLC2 were cloned from human monocytes. Briefly, total RNA from cells 
treated for 4 hours with 1µM dexamethosone was isolated using the RNeasy RNA 
isolation kit (Qiagen, Valencia, CA).  The SPT gene-specific RNA was reverse 
transcribed and PCR amplified using Superscript One-Step RT-PCR System (Invitrogen, 
Carlsbad, CA).  The following oligos were used as amplification primers:  SPTLC1 5’-
CCGGAATTCATGGCGACCGCCACGGAGCAG, SPTLC1 3’-
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CCGGAATTCGACTCTGCCTAGAGCAGGAC, SPTLC2 5’-
CCGCTCGAGATGCGGCCGGAGCCCGGAGGCTG, SPTLC2 3’-
CTAGTCTAGAGGCTCAGTCTTCTGTTTGTTC.  The SPT1 gene was cloned into 
pcDNA3.1NEO and SPT2 was cloned into pcDNA3.1ZEO.  The expression plasmids 
were transfected separately or co-transfected into HEK293 cells using Superfect (Qiagen, 
Valencia, CA) according to the manufacture’s directions.  50 µg of plasmid DNA was 
mixed with 30 µl of the Superfect reagent in 500 µl serum-free media (DMEM, 2 mM L-
glutamine) and incubated at room temperature for 15 minutes.  The liposomes were 
added to 5 ml of serum-containing media (DMEM, 10% FBS, 2 mM L-glutamine, 10 
Units/ml Penicillin, 10 µg/ml Streptomycin) and incubated on 5 x 106 HEK293 cells for 2 
hours at 37
o
C, 5% CO2.  The cells were washed and the serum-containing media was 
replaced. 400 µg/ml geneticin or 200 µg/ml zeocin were added to the culture media 48 
hours after transfection to select for cells stably expressing SPT1 or SPT2, respectively. 
The co-transfection was selected in media containing both geneticin and zeocin.  The 
media was changed every 4 days. After 2 weeks, surviving colonies were selected and 
grown in individual wells of a 6-well plate.  Three colonies for each transfection, 
SPTLC1, SPTLC2, SPTLC1/SPTLC2, pcDNA 3.1 NEO vector control and pcDNA3.1Zeo 
vector control, were selected and checked by RT-PCR for the transfected gene transcript 
and by Western blot for recombinant protein expression.  The highest expressing cell line 
for each gene transfection and vector controls were selected for further study. 
 
2.2.4 Western blotting 
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50 µg of microsomal membrane protein were loaded on a 10 % SDS-PAGE gel (BIO 
RAD, Hercules, CA). For Western blotting, the gel was transferred to nitrocellulose 
membrane using Tris-glycine buffer with 20 % methanol, as the transfer medium, for 1 
hour at 100 volts (constant), in a transfer unit (BIO RAD, Hercules, CA). After blocking 
overnight at 4 
o
C with 5% milk/TBST (Tris buffered saline with 0.05 % Tween 20) the 
membrane was incubated with rabbit anti-SPT1 serum diluted in 5% milk/TBST for 2 
hours and then with a AP-conjugated secondary antibody and its substrate using a ECF 
Western blotting kit (GE Healthcare, Piscataway, NJ).  
 
2.2.5 In vitro SPT activity assay  
 
SPT activity was assayed as previously described (31). Data of specific activity for SPT 
represent results from two or more assays conducted under the same conditions. Values 
are presented as mean with standard deviation of all acquired values.   
 
2.2.6 [
13
C]-palmitate isotope labeling 
 
Uniformly labeled [
13
C]-palmitate was mixed with fatty acid-free bovine serum albumin 
(BSA) at 1:1 molar ratio to make 1mM solution which was further diluted into 0.1mM 
with complete cell culture medium just before use and filter sterilized. Twenty-four hours 
before the experiment cells were seeded in 100-mm Petri dishes in complete growth 
medium. Just before treatment, medium was removed from the petri dish and [
13
C]-
palmitate/BSA medium mixture was applied to the cells for a certain period.   
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2.2.7 Lipid extraction 
 
The method has been described before (100, 101). The collected cells were centrifuged at 
2500rpm for 5min and the supernatant was removed. 0.5 ml of methanol and then 0.25 ml 
chloroform with internal standards were added. Samples were sonicated and incubated 
overnight at 48
o
C in heating block. After cooling down 75 µl of 1 M KOH in methanol was 
added and the sample was sonicated and incubated 2 h at 37
o
C. The sample was centrifuged 
and 400 µl of supernatant was transfered to a new glass tube for ms/ms analysis of 
sphingoid bases. The remaining sample was neutralized with 3 µl of glacial acetic acid and 
1 ml chloroform and 2 ml water were added. After sonication and centrifuge the lower layer 
was carefully removed to a new glass test tube with a pasteur pipette, leaving the interface 
(w/some water). The solvent and water were removed from all the above samples using a 
speed vac. 
 
2.2.8 Liquid Chromatography Electrospray Tandem Mass Spectrometry of 
Sphingolipids 
 
The method has been described previously (100, 101). All data was collected using a 
Perkin Elmer Series 200 MicroPump system coupled to a PE Sciex API 3000 triple 
quadrupole mass spectrometer equipped with a turbo ion-spray source.  Free sphingoid 
bases were separated by reverse phase HPLC using a binary solvent system and a 
Supelco 2.1mm i.d. x 5 cm Discovery C18 column and a flow rate of 1mL/min.  Mobile 
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phase A consisted of CH3OH/H2O/HCOOH (58:41:1) (v,v,v) with 5 mM ammonium 
formate.  Mobile phase B consisted of CH3OH/HCOOH (99:1) (v,v)  with 5 mM 
ammonium formate.  Before every run, the column was equilibrated for 0.4 min with 
60:40 (A/B) prior to injection. After sample injection (50 µL by a Perkin Elmer Series 
200 autosampler), the column was eluted with 60:40 A/B for 0.5 min, followed by a 1.8 
min linear gradient to 100% B, which was held for 5.3 min and followed by a 0.5 min re-
equilibration with 60:40 A/B before the next run.  
 
The complex sphingolipids (Cer, CMH, SM) were separated by normal phase HPLC 
using a binary solvent system and a Supelco 2.1mm i.d. x 5 cm LC-NH2 column at a flow 
rate of 1.5 mL/min.  Mobile phase A consisted of CH3CN/CH3OH/CH3COOH (97:2:1) 
(v,v,v) with 5 mM ammonium acetate.  Mobile phase B consisted of 
CH3OH/H2O/CH3(CH2)3OH/CH3COOH (64:15:20:1) (v,v,v,v) with 5 mM ammonium 
acetate. Before every run, the column was equilibrated for 0.5 min at 98:2 A/B prior to 
injection. After sample injection, the column was eluted with 98:2 A/B for 1.1 min, 
followed by a 0.2 min linear gradient to 82% A, which was held for 0.4 min, and then 
followed by a 0.8 min linear gradient to 100% B.  The column was then re-equilibrated at 
98:2 A/B for 0.5 min. 
 
In the API 3000 triple quadrupole mass spectrometer, dry ultra high-purity N2 was used 
as the nebulizing gas at a flow rate of 6 liters/min.  The ionspray needle was held at 5500 
V, and the orifice and ring voltages were kept low (30-40 V and 180-220 V, respectively) 
to prevent collisional decomposition of molecular ions prior to entry into the first 
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quadrupole, and the N2 Turbo Ion Spray gas temperature was 500 °C.  N2 was used to 
collisionally induce dissociations in Q2, which was offset from Q1 by 30-40 V.  Q3 was 
then set to pass molecularly distinctive product ions. A multiple reaction monitoring 
(MRM) method was created by setting Q1 and Q3 to pass the precursor and product ions 
of the most abundant sphingolipid molecular species.  For example, for Cer, these 
transitions occur at m/z 538.7/264.4, 566.5/264.4, 594.6/264.4, 622.7/ 264.4, 648.7/264.4, 
650.7/264.4, which correspond to Cer with a d18:1 sphingoid base and 16:0, 18:0, 20:0, 
22:0, 24:1, and 24:0 N-acyl chain, respectively.  The dwell time was 25 ms for each 
transition.  Quantitation was achieved by spiking the samples prior to extraction with the 
synthetic internal standards. 
 
Prior to selecting MRM pairs for each cell type, the variation in fatty-acyl chain length 
was determined, which allowed MRM transitions to be tailored for the major N-acyl 
species.  This was usually accomplished by precursor ion scans of m/z 184.4, the 
structure specific fragmentation indicative of SM.  SM were chosen because they are 
typically abundant and are indicative of both sphingosine (So) and sphinganine (Sa) 
based species. For example, in HEK293 cells, the major SM species are 16:0, 18:0, and 
24:1. 
 
2.2.9 Measuring cell growth rate and doubling time 
 
HEK293 and SPT1/2 cells were seeded at 4.4 x 10
5
 / 100 mm-dish. Samples were 
duplicated for each treatment. Cell number was measured every 24 hours. Medium was 
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removed from the dish and cells were washed by 10 ml of PBS, trypsinized for 3 min at 
37
o
C and resuspended in 6 ml of complete medium. After centrifuge at 1.3 rpm for 5 min, 
the cell pellet was resuspended in complete medium and applied for cell counting by a 
hemocytometer. Cells entered exponential phase 24 hours after seeding. The cell growth 
line was drawn according to the time (x-axis) and the natural logarithm of cell number (y-
axis). The cell doubling time (x) was derived from the following equations:   
N(t): The number of cells at time t    N0: the number of cells at time 0   t: cell-growing time 
N(t)  = N0 · 2 
t/x
 
ln N(t) = ln N0 + t/x · ln 2 
ln N(t) = (ln 2 /x) · t + ln N0 
ln 2/ x = slope 
x = ln 2 / slope 
Thus, the cell doubling time can be calculated from the slope of the growth curve. 
 
2.2.10 In vitro sphingomyelinase activity assay 
 
The methods for nSMase assay and aSMase assay have been thoroughly described before 
(102) and the modified part is described as below. Cells were collected in the lysis buffer 
as described (102) plus protease inhibitor cocktail (Roche, Indianapolis, IN). For our 
experiment, instead of using radiolabeled SM as a substrate NBD fluorescence labeled 
SM (C6-NBD-SM) was used at 2 nmol per 100 µl reaction. Each reaction was triplicated 
and stopped by adding 1.4 ml of HPLC solvent which is composed of 90% methanol and 
10% aqueous phase (5 mM K2HPO4). The sample was centrifuged at 2500 rpm for 8 min 
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and 1.2 ml of the supernatant was transferred to a glass HPLC sample tube. C6-NBD-SM 
and C6-NBD-Cer were diluted separately or together in the HPLC solvent as a standard. 
For each analysis 100 µl of each sample was injected into the HPLC machine and the 
isocratic flow rate of the solvent is 2 ml / min. BCA protein assay (Pierce, Rockford, IL) 
was used to determine the protein concentrations.       
 
2.2.11 In situ sphingomyelinase activity assay  
 
NBD-C6-SM was dissolved in ethanol to make 5mM solution. Fatty acid free BSA was 
dissolved in PBS to make 2mM stock solution. The two solutions were mixed at 1:1 
molar ratio and sonicated. Then the NBD-C6-SM/BSA complex was diluted to 5 µM 
working solution in complete cell culture medium and filter sterilized. Twenty-four hours 
before the experiment cells were seeded in 60-mm dishes in complete growth medium. 
Just before treatment, the old medium was replaced with the medium containing NBD-
C6-SM/BSA.     
 
2.3 Results 
 
2.3.1 Sphingolipid de novo synthesis pathway  
 
The de novo synthesis of sphingolipid starts from condensation of serine and palmitoyl-
CoA by SPT into 3-keto-Sa which is quickly reduced to Sa. Then Sa is acylated by a 
family of (dihydro)ceramide synthases (CerS) using different fatty acyl-CoAs to form the 
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corresponding DHCer subspecies (Fig 2.1). In mammals, six genes that encode CerS 
have been recently cloned (103-106). Individual ceramide synthase isoforms show 
substrate preference for specific chain length fatty acyl CoAs, thus generating distinct 
ceramides with distinct acyl-chain lengths. For example, CerS1 shows significant 
preference for stearyl-CoA (C18:0), whereas CerS5 and CerS6 preferentially catalyze the 
acylation of Sa with myristoyl- (C14:0) and palmitoyl- CoAs (C16:0) (103, 107). Then 
the different DHCer are reduced to the Cer by (dihydro)ceramide reductase (DES) and 
both DHCer and Cer are converted to complex sphingolipid (SM, DHSM, CMH, 
DHCMH) by adding different head groups. 
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Fig 2.1. Diagram of sphingolipid de novo biosynthesis pathway. D18:0 stands 
for sphingoid base backbone with 18-carbon chain and 0 unsaturated bond. C16:0 
stands for fatty acyl side chain with 16 carbons and 0 unsaturated bond.  
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2.3.2 Generation of functional HEK293/SPTLC1/SPTLC2 stable cell line  
 
Since SPT is the first as well as the key enzyme in the de novo synthesis it is interesting 
to know the impact of increasing SPT activity on the pathway. To explore this issue a 
SPT overexpression cell model was constructed. The SPTLC1 and SPTLC2 cDNA were 
cloned from human monocytes and inserted into pcDNA3.1NEO and pcDNA3.1ZEO 
separately. The expression plasmids were transfected separately or co-transfected into 
HEK 293 cells. Antibiotic selection was used to generate cells stably expressing SPTLC1 
or SPTLC2 or SPTLC1/SPTLC2. For convenience we call these cells SPT1, SPT2 and 
SPT1/2 cells separately. Using quantitative real-time PCR analysis the significant 
elevation of SPTLC1 and/or SPTLC2 mRNA were detected in these cell lines (data not 
shown). When total cell lysate was applied for SDS-PAGE followed by Western blotting 
using anti-SPT1 or anti-SPT2 antibody the protein amount of SPT1 and/or SPT2 
increased significantly in the stable transfected cells comparing with wild type as well as 
empty vector transfected HEK293 cells (Fig. 2.2).  
 
The above results showed that overexpression of SPT1 and SPT2 was successful and then 
the next question was if the overexpressed proteins were functional. Previous studies 
showed that SPT activity was mainly from the microsome fraction (108).  Microsome 
fractions were isolated from the same set of cells as those used for Western blotting for in 
vitro SPT enzyme activity assay. There was no significant change of SPT activity in 
SPT1 stable cells while a 3.5-fold SPT activity change was observed in SPT2 stable cells 
which is consistent with the previous finding that SPT2 is the catalytically active subunit 
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of the SPT enzyme (23) (Fig. 2.2). Co-expression of SPTLC1 and SPTLC2 caused SPT 
activity to increase 5-fold suggesting a synergistic effect of the two subunits, (18). The 
high SPT activity made the SPT1/2 stable cells a useful model in studying sphingolipid 
de novo synthesis and it is interesting to know the molecular consequences of it.  
 
 
 
 
 
 
 
 
2.3.3 An in situ SPT activity assay was developed using stable isotope labeling and 
LC ESI-MS/MS 
Fig. 2.2 Characterization of SPTLC transfected cell lines.   
50 µg of microsomal membrane protein from untransfected HEK293 cells (Lane 1), cells 
tranfected with  vector controls (pcDNA31.NEO, lane 2 and pcDNA3.1Zeo lane 3), 
SPTLC1 transfected cells (Lane 4), SPTLC2 tranfected cells (Lane 5), or cells co-
transfected with SPTLC1 and SPTLC2 (lane 6) was applied for Western blotting (upper 
two panels) and SPT enzyme activity assay (lower bar graph). The nitrocellulose 
membrane was probed with either anti-SPT1 antibodies (upper panel) or anti-SPT2 
antibodies (lower panel). The enzyme activity assay data represent the mean of three 
independent experiments.  
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To explore the de novo synthesis change inside the cells an in situ assay using stable 
isotope labeling was developed. Uniformly [
13
C] labeled palmitate was used as a tracer to 
follow the synthesis of sphingolipids. After taken up by a cell it can be converted to 
[
13
C]-palmitoyl CoA which is condensed with serine by SPT to form the sphingolipid 
base backbone (3-ketoSa and Sa).  [
13
C]-palmitoyl CoA can also be used to acylate a base 
backbone by (dihydro)ceramide synthase to form DHCer. If a sphingolipid molecule is 
labeled only at the base backbone we call it base labeling. If it is labeled only at fatty acyl 
chain we call it fatty acid labeling. If it is labeled at both the backbone and the fatty acyl 
chain we call it dual labeling. Using tandem MS the different labelings can be 
differentiated. Only the dual labeling and base labeling are considered from de novo 
because they are synthesized directly from serine and [
13
C]-palmitate by SPT while the 
fatty acid labeling may not be generated from that because the unlabeled base backbone 
may come from broken down of complex sphingolipids. The details of this method are 
described in “methods”. 
 
2.3.4 The dynamics of de novo synthesis of sphingoid bases in SPT1/2 cells versus 
HEK293 cells 
  
Both SPT1/2 cells and HEK293 cells were treated with [
13
C]-palmitate and collected 
every hour for 6 h. Then lipids were extracted from the cell pellets, went through a 
reverse phase C18 column and then analyzed by ESI MS/MS. The first product in the 
sphingolipid de novo synthesis pathway is 3-ketosphinganine produced by SPT but its 
amount is below the detection limit for both cell lines, which is consistent with previous 
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studies that it is rapidly reduced to Sa and there is no accumulation of it inside the cells. 
Both [
13
C] labeled and [
12
C] Sa (unlabeled) were rapidly accumulated in SPT1/2 cells, 
reached their peaks at about the same level after 2 h of [
13
C]-palmitate treatment and then 
both dropped down and leveled off (Fig. 2.3 up left panel). While in HEK293 cells [
13
C] 
Sa was under the detection limit and [
12
C] Sa was lower than that in SPT1/2 cells. 
Furthermore, both labeled and unlabeled Sa did not show any increase after [
13
C]-
palmitate treatment (Fig. 2.3 up left). However, due to the fact that the downstream 
products of Sa increased in HEK293 cells after [
13
C]-palmitate treatment (Fig. 2.4) the 
absence of Sa increase in these cells may be caused by fast conversion of Sa to complex 
sphingolipids.  
 
Sa can be converted to either dihydroceramide (DHCer) by dihydroceramide synthase or  
phosphorylated by sphingosine kinase to form Sa1P. Sa1P was not detectable in HEK293 
cells but significantly increased overtime in SPT1/2 cells (Fig. 2.3 up right). Another 
abundant sphingoid base backbone is So which is more abundant than Sa in both 
HEK293 cells and SPT1/2 cells at any time point measured. Like Sa, the amount of [
13
C] 
labeled or unlabeled So was much higher in SPT1/2 cells than in HEK293 cells (Fig. 2.3 
bottom left). However, the dynamic pattern of this sphingoid base is quite different from 
that of Sa. The unlabeled So was at least 4 fold higher than the labeled form in SPT1/2 
cells during the first 6 h of [
13
C]-palmitate treatment. There was no increase of either 
labeled or unlabeled So in SPT1/2 cells during the first hour of [
13
C]-palmitate treatment. 
Similar observation was seen for its phosphorylated product, S1P (Fig. 2.3 bottom right). 
These observations are consistent with the fact that So is derived exclusively from the 
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turnover of GSL, SM or Cer and, unlike Sa, cannot be generated through de novo 
synthesis. S1P in turn is also a product of sphingolipid breakdown. Thus unlike [
13
C]-
labeled Sa and Sa1P [
13
C]-labeled So and S1P are affected much less by the 
overexpression of SPT and do not represent the dynamics of de novo synthesis.   
 
 
 
 
 
 
2.3.5 The dynamics of de novo synthesis of complex sphingolipids in SPT1/2 cells 
versus HEK293 cells 
 
To quantify de novo synthesized complex sphingolipids, the sum of dual labeling and 
base labeling was used, which represents majority of the de novo synthesis. The first 
Fig. 2.3 The dynamics of sphingoid bases in HEK293 cells and SPT1/2 cells after 
[
13
C]-Palmitate treatment. Lipids were extracted from HEK293 cells and SPT1/2 
cells treated with 0.1 mM 
13
C-Pal for different periods of time (0~6 h) and analyzed 
for sphingoid bases by ESI-MS/MS. Both labeled (
13
C) and unlabeled (
12
C) 
sphinganine (Sa, up left), sphinganine-1-phosphate (Sa1P, up right), sphingosine (So, 
bottom left) and sphingosine-1-phosphate (S1P, bottom right) were measured. 
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complex sphingolipid along the biosynthesis pathway is dihydroceramide (DHCer) which 
is formed by acylation of Sa backbone by (dihydro)ceramide synthase. [
13
C] labeled 
DHCer in SPT1/2 cells rapidly increased during the first 2 h with [
13
C]-palmitate 
treatment, leveled off from 2 to 4 h and then dropped down about 25% (Fig. 2.4A). While 
in HEK 293 cells it increased slowly overtime and to a much less extent during the first 6 
h after [
13
C]-palmitate treatment (Fig. 2.4A). Two hours after treatment, DHCer in 
SPT1/2 cells is 40 fold higher than that in HEK293 cells. DHCer can be reduced to Cer or 
converted to more complex sphingolipids such as DHCMH and DHSM. Both DHCMH 
and DHSM were significantly increased overtime in a very similar pattern in SPT1/2 
cells and the increase in HEK 293 cells is 3~5 fold less (Fig. 2.4B, 2.4C).  
 
The de novo synthesis of Cer was increased in a similar pattern as those of DHCer in 
SPT1/2 cells and in HEK 293 cells (Fig. 2.4D). An increase of [
13
C]-labeled CMH over 
time was observed in both cell lines after treatment and was progressively faster in 
SPT1/2 cells than in HEK293 cells with a 2 to 5 fold increase from 3 h to 6 h(Fig. 2.4E). 
SM de novo synthesis was also increased over time in both cell lines, however, to our 
surprise, unlike other sphingolipids its synthesis rate was higher in HEK293 cells than 
that in the SPT1/2 stable cells (Fig. 2.4F). A further investigation on this phenomenon 
will be described below. 
 
Thus by comparing SPT1/2 cells with HEK293 cells, after 3 h of [
13
C]-palmitate 
treatment, among all the de novo synthesized complex sphingolipids the most significant 
elevation was seen in DHSM (58 fold), DHCer (25 fold) and a less elevation was seen in 
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DHCMH (6 fold), Cer(5.6 fold) and CMH (2 fold) while a decrease was seen in SM. A 
time dependent increase followed by a decrease was seen in DHCer and Cer in SPT1/2 
cells after 4 h of treatment while other species continuously elevated over time. As Sa 
started dropping down as early as 2 hours after treatment (Fig. 2.3) these data together 
suggest that either substrate depletion or feedback inhibition happened through the 
pathway.    
 
 
 
 
 
 
Fig. 2.4 The dynamics of de novo synthesis of complex sphingolipid in HEK293 cells 
and SPT1/2 cells after 
13
C-palmitate treatment  
HEK293 cells (dashed line) and SPT1/2 cells (solid line) were treated with 0.1 mM 
13
C-
palmitate for various periods of time. Lipid extractions from those cells were applied for 
LC-MS/MS analysis of DHCer (A), DHCMH (B), DHSM (C), Cer (D), CMH (E) and 
SM (F). At each time point the quantified number for each complex sphingolipid is a 
sum of the total 
13
C dual labeled subspecies and the total 
13
C base labeled subspecies. 
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In HEK293 cells de novo synthesized sphingolipid is higher than its corresponding 
dihydro-species while it is the opposite in SPT1/2 cells when the dual and base labeled 
DHCer and Cer (after 3 h of treatment) are compared in the two types of cells (Fig. 2.5). 
This observation is consistent with the above Sa data that [
13
C]-Sa is highly elevated in 
SPT1/2 cells but not HEK293 cells (Fig. 2.3). Together these results show that 
overexpression of SPT in SPT1/2 cells caused a flux of downstream molecules which 
exceeded the capabilities of the downstream enzymes. For example, the de novo 
synthesized Sa exceeded the capacity of (dihydro)ceramide synthase and DHCer 
exceeded the capacity of (dihydro)ceramide desaturase.   
 
 
 
 
 
 
2.3.6 The distribution of de novo synthesized sphingolipids with varying acyl-chain 
lengths in SPT1/2 cells versus HEK293 cells 
 
Most sphingolipids are built upon So or Sa backbone and can have various lengths of 
fatty acyl-chains. C16, C18, C20, C22, C24, C24:1, C26 and C26:1 are the most common 
Fig. 2.5 De novo synthesized dihydro-sphingolipids and their desaturated species are 
compared in HEK293 cells and SPT1/2 cells.  
Each species was quantified by a sum of 
13
C dual and 
13
C base labeling after 3 hours of 
13
C-palmitate treatment using LC-MS/MS analysis. 
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fatty acids that have been found to be incorporated into the sphingoid base backbone. 
These different subspecies of sphingolipids are first generated by acylation of Sa or So 
using different ceramide synthases (CerS) which prefer certain types of fatty acyl-CoA 
(103-106). For example, CerS1 prefers stearyl-CoA (C18) and CerS5/6 prefers palmitoyl-
CoA (C16) (Fig. 2.1). To compare the sphingolipid subspecies with varying fatty acyl 
chain lengths the sum of dual labeling and base labeling was used. Majority of [
13
C] 
labeled subspecies of each complex sphingolipid with different fatty acyl chain lengths 
were increased in SPT1/2 cells while those of SM decreased comparing with HEK293 
cells (Fig. 2.6). The chain length distribution for each kind of sphingolipid is similar 
between SPT1/2 cells and HEK293 cells. 
 
Among all the subspecies of DHCer, Cer, DHSM and SM, those with C16 fatty acyl-
chain (palmitate) are the most abundant in both HEK293 cells and SPT1/2 cells (Fig. 2.6). 
The subspecies component of DHCMH and CMH is different from that of other complex 
sphingolipids and C16 subspecies is not the dominant species in both cell lines (Fig. 2.6 
middle panel). Comparing the subspecies increases between HEK293 cells and SPT cells 
the elevation of C18 subspecies is higher than others (Fig. 2.6). Examination of fatty 
acyl-CoA showed that the amounts of labeled and unlabeled C18 acyl-CoA were 
comparable in both cells (data not shown).  We also found that the Lass1 gene which 
encodes CerS1 was increased in SPT1/2 cells by quantitative PCR analysis (data not 
shown) suggesting that elevation of SPT activity may affect the gene expression of 
downstream enzymes. 
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2.3.7 Elevation of novel sphingolipid species in SPT1/2 cells 
Fig. 2.6 Comparison of de novo sphingolipids with different fatty acyl chains in 
HEK293 cells and SPT1/2 cells.  
Lipids were extracted from HEK293 cells (white bars) and SPT1/2 cells (black bars) 
treated with 0.1 mM 
13
C-Pal for 3 h and analyzed by ESI-MS/MS. The number showed 
in the figure is a sum of 
13
C dual label and 
13
C base label, which represents the de novo 
synthesis. The x axis is the fatty acyl chain lengths and from the left to the right are 
C16, C18, C20, C22, C24:1, C24, C26:1, C26. 
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SPT prefers serine as its substrate, however, recently sphingoid bases generated from 
alanine and glycine were also identified in mammalian cells and they are quite abundant 
in cells treated with  Fumonisin B1, a ceramide synthase inhibitor (43). Condensation of 
alanine and palmitoyl-CoA by SPT generates 1-deoxy sphinganine (1-deoxySa) and its 
N-acylated form is 1-deoxy dihydroceramide (1-deoxy-DHCer). Condensation of glycine 
and palmitoyl-CoA produces 1-desoxymethyl sphinganine (1-desoxMeSa) and its N-
acylated form is 1-desoxMe-DHCer. Using [
13
C]-palmitate method we found 1-deoxy-Sa  
was dramatically elevated in SPT1/2 cells comparing with HEK293 cells (Fig. 2.7A). 
Among the [
13
C] labeled sphingoid bases 1-deoxySa was lower than So but much higher 
than other species. While, in HEK293 cells, 1-deoxySa was at the same level as all other 
species except for So (Fig. 2.7A). Both the [
13
C] base labeling and dual labeling showed 
that 1-deoxy-DHCer and 1-desoxMe-DHCer were significantly increased in SPT1/2 cells 
comparing with HEK293 cells (Fig. 2.7B). It was very impressive that the amount of 1-
deoxy-DHCer was comparable to that of Cer in SPT1/2 cells. Unlike DHCer which has 
C16 acyl-chain as its dominant subspecies, for 1-deoxy-DHCer and 1-desoxMe-DHCer 
C18 subspecies was the most abundant. 
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2.3.8 The sphingolipid change at the steady state of SPT1/2 cells vs. HEK293 cells 
 
The above data showed the de novo synthesis change of sphingolipids in SPT1/2 cells 
versus HEK293 cells. To explore the effect of SPT overexpression in the steady state the 
Fig. 2.7 Quantification of novel sphingolipid species after 
13
C-pamitate labeling.  
A. 13C labeled sphingoid bases were measured in HEK293 cells (H, white bars) and 
SPT1/2 cells (S, black bars). B. Quantification of N-acylated forms of the novel 
sphingoid bases. 1-deoxy-DHCer and 1-desoxMe-DHCer with different chain lengths 
were measured in HEK293 cells and SPT1/2 cells and compared with Cer. From the left 
to the right are the sum of all subspecies, C16, C18, C20, C22, C24:1, C24, C26:1, C26. 
The left panel is 
13
C-base labeling and the right panel is 
13
C-dual labeling. 
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SPT1/2 cells without any treatment (0 hour) were analyzed (Fig. 2.8A). Quantification of 
all the unlabeled sphingolipids species showed that they increased in SPT1/2 cells except 
for SM and DHSM and the greatest increase was seen in Cer and DHCer. Comparing 
with the de novo synthesized sphingolipids data (Fig. 2.4, 2.5) the elevation of 
sphingolipids in the steady state of SPT1/2 cells was much less and even reversed such as 
DHSM. The amount of SM was much lower in SPT1/2 cells.     
  
The proportions of complex sphingolipids were compared in HEK293cells and SPT1/2 
cells (Fig. 2.8B). From the most abundant to the least abundant species for HEK293 cells 
they are SM (65%), CMH (17%), DHSM (8%), Cer (6%), DHCer (3%) and DHCMH 
(1%) while those for SPT1/2 cells are SM (34%), Cer (28%), CMH (20%), DHCer (11%), 
DHSM (5%), DHCMH (2%). The proportion of Cer and DHCer dramatically increased 
in SPT1/2 cells while that of SM went down. Therefore, elevation of SPT activity not 
only increased the absolute value of sphingolipids but also changed the cellular 
component of the sphingolipids.  
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2.3.9 The fast growth rate of SPT1/2 cells is partially due to SPT overexpression 
 
Fig. 2.8 Comparison of sphingolipid components in HEK293 cells and SPT1/2 
cells without [
13
C]-palmitate treatment.  
Total amount of each complex sphingolipid was quantified in HEK293 cells (white 
bars) and SPT1/2 cells (black bars) without treatment (A). The distribution of 
sphingolipid species was compared in HEK293 cells and SPT1/2 cells without 
treatment (B). 
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Overexpression of SPTLC genes caused an elevation of lethal Cer which has been found 
to induce cell cycle arrest and apoptosis (3), however, the cells did not die and grow even 
faster than the untransfected HEK293 cells. The cell doubling time of SPT1/2 cells and 
HEK293 cells was measured as described in the methods part and it is 14.9 hours for 
SPT1/2 cells and 22.3 hours for HEK293 cells. Since SPT1/2 cells were generated 
through antibiotic selection it is not clear if the fast growth rate is due to SPT 
overexpression or to the selection force. To answer this question, the growth rate was 
measured when the excess SPT activity was inhibited by a SPT specific inhibitor, ISP-1. 
ISP-1 was used at 0.1 µM at which the SPT activity in SPT1/2 cells was decreased to the 
same level as that in HEK293 cells as measured by LC-MS/MS described in chapter 2. 
SPT1/2 cells and HEK293 cells were seeded at very low density in complete growth 
medium. Cell numbers were counted everyday for 3 days and growth curves were drawn 
from 24 hours to 72 hours when the growth of the cells entered exponential phase (Fig 
2.9). ISP-1 treatment slowed down the growth of SPT1/2 cells. The growth rate of the 
treated SPT1/2 cells is between that of untreated SPT1/2 and HEK293 cells with a cell 
doubling time of 18.6 hours, which suggests that the fast growth rate of SPT1/2 cells is 
partially due to the overexpression of SPT. 
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2.3.10 An open question for the decrease of SM in SPT1/2 cells 
 
An interesting phenomenon about SPT1/2 cells is that unlike other sphingolipid species 
the amount of [
13
C] labeled SM is lower than that in HEK293 cells. On the dynamic chart 
(Fig. 2.4) [
13
C]-SM is lower in SPT1/2 cells throughout all the 6 hours. Is this because 
that the sphingomyelinase activity is higher in SPT1/2 cells? To answer this question the 
activity of both acidic and neutral SMase was measured in vitro for HEK293 and SPT1/2 
cells. NBD fluorescent-labeled SM was used as a substrate and after reaction the samples 
were analyzed by HPLC.  As shown in figure 8, the aSMase activity is slightly but 
significantly higher in SPT1/2 cells than in HEK293 cells while the activity of nSMase in 
SPT1/2 cells is only about 50% of that in HEK293 cells (Fig. 2.10).  
Fig. 2.9 Growth curves for HEK293 cells, SPT1/2 cells and SPT1/2 cells treated with 
0.1 µM ISP-1.  
Cells were seeded at low density in 100 mm-dishes and a group of SPT1/2 cells were 
treated with 0.1 µM ISP-1. Cell numbers were counted everyday and growth medium 
was replaced for the remaining cells. Fresh ISP-1 was added to the treated cells in the 
fresh medium everyday. Growth rates of HEK293 cells (circle), SPT1/2 cells (square) 
and SPT1/2 cells were plotted against cell growing hours and natural logrithm of the 
number of cell.  
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It seems that the in vitro degradation of SM is faster in SPT1/2 cells than in HEK293 
cells. To confirm this result in vivo both HEK293 cells and SPT1/2 cells were incubated 
in medium containing C6-NBD-SM for 7 hours and then the cells were collected and 
extracted in methanol at 37
o
C for one hour. After centrifugation the supernatant was 
applied for HPLC analysis. All the NBD fluorescent signals were measured, normalized 
by protein amount and the percentage of SM signal over total NBD signal was calculated. 
The remaining SM was 8% in HEK293 cells and 15% in SPT1/2 cells after 7 hours of 
NBD-SM treatment, which is consistent with the in vitro assay result and suggests that 
SM degradation is faster in HEK293 cells than in SPT1/2 cells. The decrease of SM in 
SPT1/2 cells is not clear and will be discussed below. 
 
2.4 Discussion 
 
 
Fig. 2.10 Comparison of sphingomyelinase activity in HEK293 cells and SPT1/2 
cells.  
Enzyme activities of acidic sphingomyelinase and neutral sphingomelinase were 
measured in vitro using cell lysates of HEK293 cells and SPT1/2 cells. C6-NBD-SM was 
used as a substrate and after reaction the product was analyzed by HPLC. The data 
represents the mean of two independent experiments. 
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Previously overexpression of SPT has been done in mammalian cells (18, 23) however 
the impact of it on the de novo pathway has not been fully investigated. We used a 
SPTLC1/SPTLC2 overexpression cell model (SPT1/2 cells) to study the impact of SPT on 
the de novo sphingolipid synthesis. Our study showed changes of downstream molecules 
at each step. Overexpressing SPT activity increased the flux through the pathway and the 
elevation of up stream molecules exceeded the capacity of the down stream enzymes, 
which caused the flux slowing down gradually through the pathway. Futhermore, 
sphingolipid subspecies with different fatty acyl chain lengthes were measured and 
significant elevations were seen in SPT1/2 cells compared with HEK293 cells. The 
higher fold elevation of C18 subspecies and evidence of CerS1 mRNA increase in 
SPT1/2 cells (Ying Liu, unpublished data) suggest that CerS1 may be regulated by SPT 
and contribute more in the de novo synthesis than other ceramide synthases.  
 
In the past, studies have focused on So, Cer and their derivatives which were potent 
bioactive lipids involved in cell growth, death, senescence, adhesion, migration, 
inflammation, angiogenesis and intracellular trafficking (3, 109, 110). Recently, Sa, 
dihydro-sphingolipids and their derivatives which usually exist at a very low level inside 
the cells have been found to be bioactive (92, 93, 111). De novo synthesized sphinganine 
and dihydro sphingolipids have been found to play a role in 4HPR induced cancer cell 
apoptosis (92). De novo generated Sa and DHCer were increased in celecoxib, a COX-2 
specific inhibitor, treated tumor cells and may contribute to the anti-proliferative effects 
of celecoxib (93). L-threo-sphinganine, a synthetic stereoisomer, induces autophagy in 
solid tumor cells (111). So far few studies have analyzed those species, furthermore, 
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traditional thin layer chromatography method cannot differentiate dihydro-species with 
the desaturated species, which might have masked the effect of dihydro-species in some 
studies.    
 
Some novel de novo synthesized sphingolipids, such as 1-deoxySa which only exist at a 
low level in certain mammalian cells, were also identified in [
13
C]-pamitate treated 
SPT1/2 cells and surprisingly the amount of 1-deoxyDHCer was comparable to Cer. 
These observations suggest that the highly expressed SPT and the exogenous [
13
C]-
palmitate might cause a fast consumption of the introcellular serine and thus alanine and 
glycine which have structural similarity to serine were used as a substrate.  Recently it 
was reported that 1-deoxySa (spisulosine) isolated in sea mollusc Spisula polynyma 
induced prostate tumor cell death by de novo synthesis of Cer (112). Our result suggests 
that mammalian SPT can generate 1-deoxySa under certain circumstances. It would be 
interesting to know what the targets of the novel compound are.  
 
The de novo synthesis of all other sphingolipids increased in SPT1/2 cells while that of 
SM decreased. This is not caused by elevated degradation of SM as seen in the above 
data or by impairment in SM synthesis because the synthesis of DHSM which uses the 
same SM synthase is dramatically increased in SPT1/2 cells (Fig. 5C, 6). We noticed that 
the ratio of DHCer to Cer is higher in SPT1/2 cells than that in HEK293 cells after 
palmitate treatment. Since the DHCer and Cer share the same transporter, CERT, from 
ER to Golgi (113, 114) is it possible that DHCer and Cer might compete for the binding 
site of CERT? One might argue that CMH and DHCMH (mainly GlcCer) are also 
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synthesized in Golgi and why they do not compete for each other. This is probably 
caused by a different transportation mechanism which is not clear yet and might involve 
vesicle transportation (115).   
 
It is interesting that SPT1/2 cells did not show any cytotoxicity with the accumulation of 
cytotoxic sphingolipid molecules as Cer. The cells grow fast and show a morphology 
change comparing with the HEK293 cells. No toxicity was observed in SPT1/2 cells even 
after 36 hours of [
13
C]-palmitate treatment. How the SPT1/2 cells handle the large 
amount of sphingolipids is still an interesting question.    
  
2.5 Conclusions 
 
Overexpression of SPTLC1 and SPTLC2 in HEK293 cells (SPT1/2 cells) elevated SPT 
enzyme activity. 
 
The dynamics of de novo synthesis of sphingolipids was measured in both HEK293 cells 
and SPT1/2 cells after cells were treated with [
13
C]-palmitate. 
 
The de novo synthesized sphinglipids were increased more rapidly and significantly in 
SPT1/2 cells than in HEK293 cells except for SM.  
 
Sphingolipid subspecies with different fatty acyl-chains were compared in the two cell 
types and C18 subspecies were elevated more than other subspecies in SPT1/2 cells.  
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The amount of each dihydro-species was lower than that of its desaturated form in 
HEK293 cells but higher in SPT1/2 cells. 
 
The slow increase of SM in SPT1/2 cells is not caused by increased SM degradation and 
might relate to the substrate pool change. 
 
SPT used not only serine but also alanine and glycine as its substrate to synthesize novel 
sphingolipid species in vivo.  
 
Overexpression of SPT caused accumulation of cytotoxic sphingolipids but the cells did 
not die and instead they grow faster. 
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CHAPTER 3 
 
SPT1 is present in ER, nucleus and focal adhesions, and functions in cell 
morphology  
 
3.1 Introduction  
 
Sphingolipids are a complex family of compounds that play important roles in membrane 
structure, biological recognition, cell adhesion, and cell regulation as participants in 
signaling, membrane trafficking, autophagy and other processes (3-5, 13, 109). In some 
cases, complex sphingolipids (glycosphingolipids and sphingomyelins) affect cell 
behavior by associating with membrane microdomains that contain receptors, 
transporters, and other signal transducers such as Src family kinases, small G-proteins 
(e.g., RhoA, Ras), and focal adhesion kinase (13).  In other cases, the lipid backbones and 
related metabolites (e.g., ceramide, ceramide 1-phosphate, sphingosine 1-phosphate, and 
sphingosine) serve as first and second messengers (3, 109, 110) for behaviors such as cell 
migration and the associated actin stress fiber formation and focal adhesion formation 
(116-118).  These are often orchestrated by changes in the membrane dynamics of the 
pertinent sphingolipids as well as their trafficking, metabolic remodeling and de novo 
sphingolipid biosynthesis (3). 
 
Sphingolipid biosynthesis is initiated by condensation of L-serine with palmitoyl-CoA by 
SPT.  In mammalian cells, SPT is thought to be a membrane bound heterodimer 
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comprised of two subunits, SPT1 and SPT2, with molecular weights of 53 kDa and 63 
kDa, respectively (17, 18), but in some cells, an additional subunit, SPT3, has also been 
noted (19).  SPT is often described as an enzyme of the endoplasmic reticulum (ER) 
because enzymatic activity has been found primarily in microsomes (31, 108), and 
hemaglutinin (HA)-tagged SPT1 has been localized to the ER when expressed in Chinese 
hamster ovary cells (18).  Nonetheless, immunohistochemical analyses of different 
tissues and cells using the antibodies for SPT1 have found cross-reacting species in not 
only the cytoplasm (i.e., ER at this resolution) but also the nucleus (98, 119) and focal 
adhesions (120).  Furthermore, a recent study (121) has detected an interaction of SPT1 
with ABCA1. 
 
This study establishes that SPT1 is, indeed, found in these surprising locations using 
siRNA suppression of SPT to confirm the specificity of the antibody staining, which also 
results in cell rounding and detachment.  SPT1 is not only colocalized with vinculin by 
immunofluorescence staining but also coimmunoprecipitated with vinculin in HEK293 
cells. The localization of SPT1 with focal adhesions is seen in growing but not confluent 
cells in culture, and reappears when cell migration is induced by a scratch-wound healing 
assay. Thus, these studies have found that SPT1 has cell functions beyond its already 
known catalysis of the first step of de novo sphingolipid biosynthesis in the endoplasmic 
reticulum.  
 
3.2 Materials and methods  
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3.2.1  Materials 
The affinity purified polyclonal rabbit anti-human primary antibodies raised against SPT1 
peptides have been previously described (98). Anti-BiP antibody was from StressGen, 
Inc. (Victoria, BC, Canada). Anti-vinculin antibody was from Sigma Aldrich (Saint Louis, 
MO) and anti-ABCA1 antibody was from Novus Biologicals. The secondary antibodies 
were Alexa Fluor-conjugated goat anti-rabbit and anti-mouse obtained from Molecular 
Probes, Inc. (Eugene, OR). The nucleic acid dye Hoechst 33342 (Invitrogen, Carlsbad, 
CA). SPT1 epitope peptides were from Abgent (San Diego, CA). 
 
3.2.2 Cells and cell culture 
 
The HEK293, HEK293T and HeLa cells were obtained from the American Type Culture 
Collection (Manassas, VA).  HEK293 cells were grown in DMEM/F12 medium (1:1) 
(Gibco BRL, MD) supplemented with 10% fetal bovine serum (FBS), penicillin (100 U / 
ml) and streptomycin (100 µg /ml) at 37 °C in a humidified 5 % CO2 atmosphere. HeLa 
cells and HEK293T cells were grown in Dulbecco's minimum essential medium (DMEM; 
Gibco BRL, MD) with the same supplements.  
 
3.2.3 DNA constructs 
 
SPTLC1 cDNA was obtained from Origene. To generate N-terminal GFP-tagged SPT1 
the SPTLC1 gene was amplified by using the following primers: 5’-
ATGGCGACCGCCACGGAGCAGTGG-3’ and 5’-
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GCCTAGAGCAGGACGGCCTGGGCT-3’. The PCR fragment corresponding to the 
coding sequence (CDS) of SPTLC1 was cloned into pEGFP-C2/SmaI (Clontech, 
Mountain View, CA) resulting in pEGFP-C2-SPT1.  
For C-terminal GFP-tagged SPT1, SPTLC1 gene was first amplified using the primers:  
5’-ATGGCGACCGCCACGGAGCAGTGG-3’ and 5’-
GAGCAGGACGGCCTGGGCTACCTC-3’. The PCR fragment of SPTLC1 was then 
subcloned into the pUC18 cloning vector. It was next digested from the pUC18 vector by 
using BamHI and EcoRI restriction enzymes and subcloned into the same sites in pEGFP-
N1 to generate pEGFP-N1-SPTLC1.  
 
To create small peptide-tagged SPT1, pCMV-MAT-FLAG vector was used (Sigma 
Aldrich, Saint Louis, MO). SPTLC1 was first amplified by the following primers: 5’-
ATGGCGACCGCCACGGAGCAGTGG-3’ and 5’-
TAAGCGTAATCTGGAACATCGTATGGGTAGAGCAGGACGGCCTGGGCTACCT
C-3’, the latter contains a HA sequence. The PCR fragment corresponding to the CDS 
of SPTLC1 was then cloned into pCMV-MAT-FLAG/EcoRV resulting in pCMVMAT-
FLAG-SPTLC1-HA.  
 
To construct internal tagged SPT1, the 5’-end of SPTLC1 gene was first amplified by 5’-
GGATCCGCCACCATGGCGACCGCCACGGAGCAGTG-3’ and 5’-
GATATCAGCGTAATCTGGAACATCGTATGGGTAAGCGTAATCTGGAACATCG
TATGGGTAAGCGTAATCTGGAACATCGTATGGGTATCCATTCACCACAGTTTT
GTGGCTTG-3’. The forward primer contains BamHI site and the reverse primer has 
 58 
three HA sequences. The 3’-end of SPTLC1 was amplified by the following primers: 5’-
CATACGATGTTCCAGATTACGCTGATATCAAAGAATGTATAAACTTCGCCTCA
TTTAATTTTC-3’ and 5’-CTAGAGCAGGACGGCCTGGGC-3’. The forward primer 
has an overlap sequence with the previous reverse primer. The overlap extension was 
completed by using the same forward primer from the first pair and the same reverse 
primer from the second pair to amplify SPTLC1 gene from the beginning to the end. Then 
the amplified CDS was cleaved by BamHI and inserted into pcDNA 3.1 vector 
(Invitrogen, Carlsbad, CA). 
  
All of the above have been sequenced to confirm the fidelity of the constructs. 
 
3.2.4 Generation of SPTLC1 and SPTLC2 over-expressing cell line 
 
HEK293 cells stably overexpressing SPTLC1/SPTLC2 were generated as described in 
Chapter 2. 
  
3.2.5 Immunofluorescence confocal microscopy 
 
Cells were cultured on collagen (BD, San Jose, CA) coated glass coverslips (VWR, Inc., 
West Chester, PA) in a 24-well plate and fixed with 4 % formaldehyde in PBS at room 
temperature for 15 min. Fixed cells were permeabilized with 0.1  % Triton X-100 for 5 
min, blocked in 10 % fetal calf serum in PBS (serum-PBS) for 30 min and then subjected 
to indirect immunofluorescence staining. Cells were incubated for 1 h at room 
 59 
temperature, with primary antibody diluted in PBS-serum, then the cells were washed 3 
times with PBS-serum for 5 min each, and incubated for 1 h at room temperature with 
Alexa Fluor-conjugated secondary antibody. Nucleic acids and actin were stained by 
incubating fixed cells with PBS containing 1 µg/ml Hoechst 33342 dye and rhodamine 
phalloidin (Invitrogen, Carlsbad, CA). Stained cells were rinsed in PBS and mounted in 
Fluoromount G (Southern Biotechnology Associates, Inc., Bermingham, AL) before 
observing under a Zeiss LSM 510 inverted laser scanning confocal microscope 
(Heidelberg, Germany) equipped with a Zeiss Plan-Apochromat 43 x oil immersion 
objective lens, and controllers for setting the band excitation and emission of 
wavelengths in the green, red and blue regions. Slides were scanned in “line mode” and 
then singled at an average of 16 scans to eliminate background noise. Images were 
collected with the resident Zeiss confocal microscope software. 
 
3.2.6 Western blotting 
 
Equal amounts of protein (30 µg) from each fraction and 50 µg of total cell lysate were 
loaded on a 12 % SDS-PAGE gel (Pierce, Rockford, IL). For Western blotting, the gel 
was transferred to the nitrocellulose membrane using a Tris-glycine buffer with 20 % 
methanol as the transfer medium, for 1 h at 100 volts (constant), in a transfer unit (BIO 
RAD, Hercules, CA). The blot was blocked overnight at 4 
o
C with SuperBlock blocking 
buffer (Pierce, Rockford, IL). The membrane was then incubated with rabbit anti-SPT1 
serum diluted in SuperBlock and incubated for 2 h at room temperature. The membrane 
was rinsed three times in Tris buffered saline with 0.05 % Tween 20 (TBST) and 
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incubated for 1 h at room temperature, with a peroxidase-conjugated secondary antibody 
(Pierce, Rockford, IL). Finally, the membrane was rinsed in TBST and incubated in 
Supersignal West Pico chemiluminiscent reagent (Pierce, Rockford, IL). 
 
3.2.7 Peptide competition assay 
 
The SPT1 epitope peptides KLQERSDLTVKEKEEC (45~59 aa) and 
KEQEIEDQKNPRKARC (222~236 aa) were synthesized by Abgent (San Diego, CA). 
Each peptide was dissolved in PBS/10 % serum to a final concentration of 20 µg/ml for 
the competition experiments. The antibody-peptide mixture was incubated overnight at 
4oC and then applied for immunostaining following the standard protocol. 
 
3.2.8 Coimmunoprecipitation 
 
Immunoprecipitation procedure was modified from the standard protocols (122, 123). 
Cells that were 60% confluent in 100-mm dishes were rinsed with ice-cold PBS and then 
scraped in 0.6 ml of ice- cold RIPA buffer (50 mM Tris-HCl, pH 7.4; 1% NP-40; 0.25% 
Na-deoxycholate; 150 mM NaCl; and 1 mM sodium orthovanadate) with protease 
inhibitor cocktail (Roche, Indianapolis, IN), and the cell lysate was centrifuge at 16,000 x 
g at 4
 o
C for 15 min to prepare the supernatant for the co-immunoprecipitation studies. 
The cell lysate was cleared of proteins that bind non-specifically by mixing 0.5 ml of the 
supernatant with 50 µl of a 50% protein G-sepharose bead slurry (Sigma Aldrich, Saint 
Louis, MO) for one hour and then centrifuged at 16,000 x g for 5 min.  In another 
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microcentrifuge tube 50 µl of the 50% protein G-sepharose bead slurry was incubated 
with the antibody of interest (4 µg of mouse anti-vinculin antibody, Sigma Aldrich, Saint 
Louis, MO, or mouse anti-V5 antibody, Invitrogen, Carlsbad, CA, as a control) for 2 
hours at 4
o
C and centrifuged at 16,000 x g for 5 sec (the following centrifugations were at 
the same condition). The antibody-conjugated beads were washed 3 times with 1 ml of 
ice-cold RIPA buffer and the supernatant was removed. Then the antibody-conjugated 
beads were mixed with 0.5 ml pre-cleared cell lysate and 0.5 ml of PBS and incubated 
overnight at 4
o
C. After 3 times of washing with ice-cold RIPA buffer and one time 
washing with ice-cold PBS the complex beads were centrifuged down and the 
precipitated proteins were eluted with 40 µl of laemmli sample buffer (Biorad, Hercules, 
CA) by boiling at 95
o
C for 5 min. After centrifugation the supernatant was transferred into a 
new tube and 25% of it was applied for SDS-PAGE. 
 
3.2.9 siRNA transfection 
 
The day before transfection HEK293 cells were seeded on collagen-coated coverslips in a 
24-well plate at 4 x 104 per well. Three different SPTLC1 siRNA probes (Ambion, 
Austin, TX) targeting to exon 4 or 5 were pooled. The cells were transfected with the 
SPTLC1 siRNA pool or non-specific control siRNA (Ambion, Austin, TX) at 100 nM 
using DharmaFECT 1 transfection reagent (Dharmacon, Lafayette, CO). Mock 
transfection was performed with transfection reagent alone. Cell culture medium was 
replaced after 48 h of transfection. Cells were fixed for immunofluorescence staining 
after 72 h of transfection. 
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3.2.10 Subcellular fractionation 
 
For a crude subcellular fractionation of the siRNA transfected cells, three 100-mm dishes 
were transfected with each kind of siRNA as above and after 72 h the cells were washed 
in PBS then scraped from the dishes in hypotonic buffer (20 mM Hepes, pH 7.9, at 4 
o
C, 
1.5 mM MgCl2, 10 mM KCl, 0.5 mM DTT) plus protease inhibitor cocktail, Complete 
Mini (Roche, Indianapolis, IN) and homogenized by 30 strokes of a Dounce homogenizer. 
Nuclei were recovered by centrifugation at 1000 x g for 15 min and washed once using 
Nuclei Wash Buffer (10 mM Hepes, pH 7.9 at 4 
o
C, 0.2 mM MgCl2, 10 mM KCl, 0.5 
mM DTT, and protease inhibitor cocktail) and centrifuged as the crude nuclear fraction.  
The post-nuclear fraction was then centrifuged for 1 h at 100,000 x g, the supernatant was 
defined as the cytosoluble fraction, and the pellets resuspended in the same buffer as the 
membrane fraction. All the fractions were stored as aliquots at -80
o
C (124, 125). 
 
3.2.11 Cell viability assay 
 
The floating cells were collected from three 100-mm dishes 48 h after siRNA transfection, 
centrifuged, suspended in 0.1 % trypan blue. Both the viable cells and the unviable cells 
were counted using a hemocytometer. 
 
3.2.12 Lipid extraction and analysis by LC-ESI MS/MS 
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The method has been described in the previous chapter. Briefly, the cells were collected 
in PBS and lipids were extracted in methanol/chloroform. The mass spectrometry data 
were collected using a PE Sciex API 3000 triple quadrupole mass spectrometer equipped 
with a turbo ion-spray source. As the first step of the analyses, the cells were examined 
by precursor ion scans for m/z 264.4 and 266.4 through the ceramide and 
monohexosylceramide range, and by precursor ion scans of m/z 184.4 for 
sphingomyelins to identify the major subspecies.  Then for quantitative analysis, samples 
that had been spiked with an internal standard cocktail (from Avanti Polar Lipids, 
Alabaster, AL) were analyzed by LC ESI-MS/MS using a multiple reaction monitoring 
program built to encompass the subspecies of these sphingolipids found in the extracts 
(101). 
 
3.2.13 Wound healing assay 
 
HeLa cells were grown on collagen coated glass coverslips until confluent and a pipette 
tip was used to scratch the plate and the medium was replaced to remove the floating 
cells (126). Three hours after scratching the cells were fixed and processed for 
immunofluorescence staining and confocal microscopy. 
 
3.2.14 Transfection of plasmid DNA 
 
The transfection was done according to GeneJuice transfection protocol. The DNA to be 
transfected should be at a concentration of 0.5–1 µg/µl; if the DNA concentration is lower, 
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decrease the volume of serum-free medium in the transfection mix to compensate for the 
larger volume of DNA.  
 
The day before transfection glass coverslips were placed in a 24-well plate. 3 × 10
4 
cells 
were seeded in complete growth medium per well and incubated at 37°C (5% CO2) 
overnight. Cells were 50% confluent before transfection. For each well to be transfected, 
serum-free medium was placed into a sterile tube. GeneJuice was added
 
drop-wise 
directly to the serum-free medium and thoroughly mixed by vortexing. The mixture was 
incubated at room temperature for 5 min. For each well to be transfected, 0.25 µg DNA 
was added to GeneJuice/serum free medium mixture and mixed by gentle pipetting. The 
mixture was incubated at room temperature for 10 min and then added drop wise to the 
cells in complete growth medium. The dish was gently rocked to ensure even distribution. 
The cells were incubated for 48 h at 37°C (5% CO2). 
 
3.3 Results 
 
3.3.1   Native cell lines display novel subcellular localizations for endogenous SPT1 
 
As has been done before (18), we initially examined SPT localization using SPT1/2 cells, 
a HEK293 cell line that stably overexpresses SPTLC1 and SPTLC2 as described under 
“materials and methods”. As shown in Figure 3.1A, the immunofluorescence produced 
by the anti-SPT1 antibodies (98, 119) overlapped with BiP, a marker for the ER (127), 
which agreed with the previous localization of a stably overexpressed SPT1 with epitope 
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tags at either the N or C terminus (18).  However, when untransfected HEK 293 cells 
were examined, the results (shown in Figure 1B) revealed some immunostaining in the 
cytoplasm (consistent with SPT1 in the ER), however, a substantial amount of 
endogenous SPT1 appears to be in the nucleus (based on co-localization with the DNA 
intercalating dye Hoechst 33342), and as punctate dots at the periphery of the cell at what 
appear to be the convergence points for actin stress fibers (stained red with phalloidin), 
which are referred to as focal adhesions (128).  The SPT1 immunostaining at the cell 
periphery clearly co-localized with a focal adhesion marker protein, vinculin, as shown in 
Figure 1C.  
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These findings were not an anomaly of these HEK cells because the same results were 
obtained using HEK 293T cells and HeLa cells (Figure 3.2A).  In agreement with the 
original characterization of the antibody (98, 119), immunostaining was not seen with 
pre-immune serum, as shown in Fig. 2B for HEK 293 cells (similar images for the other 
Fig. 3.1 Intracellular localization of SPT1 in SPTLC1&SPTLC2 overexpressing 
HEK293 cells and native HEK293 cells by immunofluorescence staining and 
confocal microscopy.  
Cells were grown on glass coverslips for 24 h before collecting for immunostaining. 
Rabbit anti-SPT1 antibody was used as primary labeling and Alexa Fluor 488 anti-rabbit 
antibody (green) as secondary labeling. (A) Localization of SPT1 in HEK293/SPTLC1/2 
stable cells. SPT1 protein was stained in green and the ER marker protein, Bip, was 
labeled with Alexa Flour 568 (red). (B) Localization of endogenous SPT1 proteins in 
HEK293 cells. SPT1 was labeled in green. Actin was labeled by rhodamin phalloidin 
(red) and the nucleus was by Hoescht 33342 (blue). The arrows point to the focal 
adhesion localization of SPT1 at the tips of actin stress fibers. (C) Co-localization of 
SPT1 and vinculin in HEK293 cells. Mouse anti-vinculin antibody was used as a primary 
labeling followed by Alexa Flour 568 anti-mouse antibody (red). The images were taken 
by Zeiss confocal microscope. Bar, 10 µm. 
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two cell lines are not shown). Furthermore, the majority of the immunostaining was 
eliminated by incubating the antibody with an excess amount of the peptides that were 
used in the immunization to prepare this antiserum prior to immunostaining (as illustrated 
for HeLa cells in Fig. 3.2). The polypeptides that were used to prepare these anti-SPT1 
antibodies (as described under “materials and methods”) do not appear in any other 
known proteins, including SPT2 and SPT3, as determined by protein blast analysis; 
therefore, it is unlikely that these results are due to immuno-cross-reactivity with another 
protein, although this cannot be asserted conclusively until further analyses are performed 
(see below).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.2 SPT1 staining in HEK293T cells and HeLa cells and the results with pre-
immune serum   
(A) Confocal image of SPT1 in HEK293T cells and HeLa cells by rabbit anti-SPT1 
antibody labeled by Alexa Fluor 488 anti-rabbit antibody (green). Actin was labeled by 
rhodamin phalloidin (red) and the nucleus was by Hoescht 33342 (blue). (B) Pre-immune 
serum staining of HEK cells followed by Alexa Fluor 488 secondary labeling. Bar, 10 
µm. 
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3.3.2 Coimmunoprecipitation of SPT1 and vinculin in HEK293 cells 
To further confirm the focal adhesion localization of SPT1, coimmunoprecipitation was 
used. Vinculin was precipitated by mouse anti-vinculin antibody conjugated protein G 
sepharose beads (Fig. 3.4, right lane). Mouse V5 antibody conjugated protein G 
sepharose beads were used as a nonspecific control and protein G sepharose beads alone 
were used as a negative control. The precipitate was immunoblotted with anti-vinculin 
antibody, our rabbit anti-SPT1 antibody, and a commercial rabbit anti-SPT1 antibody 
(Abnova). As shown in Figure 3.4, vinculin was successfully precipitated (bottom panel) 
and both anti-SPT1 antibodies detected SPT1 on the membrane (top and middle panels). 
No band was detected from the precipitate of nonspecific control or the negative control 
(middle and left lane).  
Fig. 3.3 The effect of adding SPT1 polypeptides to block SPT1 binding by the SPT1 
antibody   
The rabbit anti-SPT1 antibody was incubated with epitope specific peptides (aa 45~59, 
aa 222~236) in blocking buffer and then applied for primary labeling of HeLa cells 
followed by Alexa Fluor 488 anti-rabbit antibody. For control, the antibody was 
incubated with blocking buffer only. Bar, 10 µm.   
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3.3.3  Confirmation of the novel localization of SPT1 by siRNA silencing of the 
expression of SPT1 
 
As shown in Figure 3.5, when HEK293T cells were transfected with siRNA against 
SPTLC1 or a combination of siSPTLC1 and siSPTLC2 (i.e., against both subunits of SPT), 
then immunostained with the anti-SPT1 antibody, there was a substantial decrease in the 
overall fluorescence of the cells (middle and lower panels of Fig. 3.5A) versus cells 
treated with a non-specific siRNA control (top panel of Fig. 3.5A).  Indeed, fluorescence 
in the nucleus and focal adhesions appeared to be suppressed the most by siSPTLC1 and 
siSPTLC1/siSPTLC2; however, the SPT specific siRNAs caused cell rounding, which 
obscures some of the decrease in SPT1 in the cytoplasm/ER. Western blotting of total 
cell lysates confirmed that the amount of ~53 kDa SPT1 protein decreased significantly 
in the siSPTLC1 and siSPTLC1/siSPTLC2 transfected cells compared with the non-
specific siRNA transfected cells (Fig. 3.5B left).  Decreases were also seen when the 
Fig. 3.4 Coimmunoprecipitation of SPT1 and vinculin  
Vinculin was precipitated from HEK293 cell lysate using mouse anti-vinculin antibody 
bound protein G sepharose beads (right lane). Mouse V5 antibody was used as a 
nonspecific control antibody (middle lane) and protein G sepharose alone was used as 
negative control (left lane). The immunoprecipitate was applied for SDS-PAGE and 
immunoblotted with our rabbit anti-SPT1 antibody (top panel), commercial rabbit SPT1 
antibody (middle panel) and anti-vinculin antibody (bottom panel).  
IP:  Vin    V5    Non
Anti-SPT1
Anti-Vinculin
Anti-SPT1 (A)
55 kD
55 kD
120 kD
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Western blotting was conducted using crude nuclei and membranes (Fig. 3.5B right), 
with the nuclear immunostaining appearing to be depleted the most, which is similar to 
what is seen by confocal microscopy (c.f. middle panels of Fig. 3.5A).  Thus, these 
observations confirm that the SPT1 immunostaining in focal adhesions and the nucleus is 
due to SPT1 in those regions of the cell.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.5 Confocal imaging of SPT1 in HEK293T cells transfected with siRNA to 
silence SPTLC1   
(A) HEK293T cells grown on collagen coated coverslips were transfected with non-
specific siRNA, siSPTLC1 and siSPTLC1/siSPTLC2 separately for 72 h and then fixed 
for immunofluorescent staining using anti-SPT1 antibody and Alexa Fluor 488 anti-
rabbit antibody (green) as well as for actin fibers (phalloidin) and nuclei (Hoechst 3342) 
(Bar, 10 µm); or (B) analyzed by Western blotting for SPT1 normalized by actin. The 
right immunoblot is for the nuclear and membrane fractions isolated from HEK293T 
cells transfected with either non-specific siRNA or siSPTLC1 as described in 
experimental procedures.   
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3.3.4  SPT1 suppression using siSPTLC1, but not siSPTLC2 silencing, induces cell 
rounding followed by detachment 
 
Suppression of SPT1 by siRNA for SPTLC1 alone, or the combination of siRNAs for 
SPTLC1 and SPTLC2, causes cell rounding as observed by confocal (Figure 3.5) or light 
microscopy (Figure 3.6A).  Since it is not clear whether the changes in morphology are 
due to loss of SPT1 per se or to its indirect effect on SPT2, which is known to be bound 
and stabilized by SPT1 (129), the effect of silencing SPT2 alone was evaluated.  When 
HEK293T cells were transfected with siSPTLC2 alone, there was no noticeable cell 
rounding (Figure 3.6A), despite the almost complete disappearance of the ~63 kDa SPT2 
polypeptide (Figure 3.6B).  Therefore, suppression of SPT1 but not SPT2 has this impact 
on cell morphology.  
 
In addition to causing cell rounding, siSPTLC1 and the combination of siSPTLC1 & 2 
caused a noticeable increase in the number of cells that had detached from the dish after 
~48 h (data not shown).  This did not appear to be due to cell death because the floating 
cells were ~70% viable based on the Trypan blue exclusion assay; however, when the 
floating cells were collected and replated in new medium minus the siRNA(s), they did 
not survive.  These observations suggest that the cell rounding upon suppression of SPT1 
facilitates cell detachment and death, presumably due to anoikis after loss of cell-matrix 
interactions (130).  
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3.3.5 The change in cell morphology induced by siSPTLC1 is not due to reduction of 
the sphingolipid amounts of the cells  
 
To determine how siRNAs for SPT1 and 2 affect the sphingolipid content of the cells, 
HEK293T cells were treated with transfection reagent alone, non-specific siRNA or 
Fig. 3.6 Morphology of HEK293T cells after transfection with control and SPTLC 
siRNAs.  
(A) Phase contrast images of HEK293T cells transfected with non-specific siRNA, 
siSPTLC1, siSPTLC2 and siSPTLC1/siSPTLC2 separately.  (B) The Western blots that 
show that SPT2 protein has been suppressed by siSPTLC2 alone and in combination with 
siSPTLC1, with normalization using actin.   
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siSPTLC1 and/or 2 then analyzed by liquid chromatography-electrospray tandem mass 
spectrometry (LC-ESI MS/MS) (Fig. 3.7).  Compared to the non-specific siRNA, 
siSPTLC1 did not reduce the amount of total sphingolipids (defined as the major species 
sphingomyelin + monohexosylceramide + ceramide), but the total sphingolipid content of 
the siSPTLC2 treated cells was somewhat lower (~17%, P = 0.06).  Ceramides were 
lower for all of the cells treated with for siSPTLC1 (13%), siSPTLC2 (35%) or both 
(40%), as might be anticipated to occur upon suppression of de novo biosynthesis of 
ceramide.  These findings are consistent with previous findings that when de novo 
biosynthesis is eliminated, cells can still survive when supplied medium containing serum 
sphingolipids (129).   
 
Thus, since siSPTLC2 caused a greater change in the sphingolipid content of the cells 
than siSPTLC1 alone, which is the opposite of the effects of these siRNAs on cell 
morphology, it is unlikely that the cell rounding is induced by changes in sphingolipid 
metabolism versus a reduction in SPT1 per se.   Consistent with this conclusion, 
treatment of HEK293 cells with myriocin, a potent inhibitor of SPT that essentially 
eliminated de novo sphingolipid biosynthesis, did not change cell morphology for up to 
48 h (data not shown). 
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3.3.6 Appearance of SPT1 in focal adhesions decreases as cells in culture reach 
confluence and increases with induction of cell migration 
Fig. 3.7  Amounts of ceramide, monohesoxylceramides and sphingomyelins in 
HEK293T cells after transfection with control vectors or siSPTLC1 and/or 
siSPTLC2.  
HEK293T cells were transfected with non-specific siRNA, siSPTLC1, siSPTLC2 
and siSPTLC1/SPTLC2 separately for 72 h and then collected for lipid extraction 
and analysis by LC ESI MS/MS.  The amounts are given as the mean + SD for 
analysis of 2 dishes. 
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As illustrated in Figure 3.8A, the focal adhesion staining of SPT1 disappears when the 
cells grow to confluence (with little difference in the staining of the nucleus and 
cytoplasm/ER) compared to cells at lower density (Figure 3.8B).  The percentage of cells 
with focal adhesion staining for SPT1 before confluence (i.e., before the cells are 
completely surrounded by other cells) was essentially the same for HEK293 cells (95%) 
and HeLa cells (90%), whereas, neither cell type had any detectable SPT1 with focal 
adhesions after they were confluent.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.8  Focal adhesion staining of SPT1 in low density cells and confluent cells.   
(A) Confocal fluorescence imaging of SPT1 in confluent HeLa cells.  HeLa cells 
were grown on collagen coated coverslips until confluent and then fixed for 
immunofluorescent stain with anti-SPT1 antibody followed by Alexa Fluor 488 anti-
rabbit antibody (note enlarged image).  (B) SPT1 in low density cells. Cells were 
cultured at low density before applied for immunofluorescence staining. The two 
cells shown here appear to be at a late stage of mitosis. Actin fibers and nuclei were 
labeled by rhodamine phalloidin and Hoechst 3342 separately. Bar, 10 µm.   
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The dynamic of SPT1 localization was also examined using the scratch-wound healing 
assay to induce cell migration (126). HeLa cells were grown to confluence on collagen 
coated glass coverslips, scratched to produce an open furrow using a pipette tip, and then 
the cells were incubated for 3 h before being fixed and stained. Confocal imaging of the 
cells (Fig. 3.9) showed that the focal adhesion staining of SPT1 appears mainly at the tips 
of actin stress fibers at the migrating edges of the cells along the wound gap (Fig. 3.9), 
whereas little or none was seen in cell-cell junctions away from the wound edge, nor in 
any of the confluent cells away from the site of the scratch.  
 
These images provide compelling evidence that the SPT1 in focal adhesions is associated 
with, and plays a role in, cell morphology and migration. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.9 Focal adhesion staining of SPT1 during the scratch wound-healing assay. 
HeLa cells were grown to confluent on collagen coated glass coverslips, scratched by a 
pipet tip, and processed for immunofluorescence staining using anti-SPT1 antibody 
after 3 h. Bar, 10 µm. The bottom image is an enlarged one.  
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3.3.7 Partial co-localization of ABCA1and SPT1 in the cell periphery 
 
ABCA1 was first identified on plasma membrane and later in multiple subcellular 
locations. It has recently been reported that SPT1 can be found in ABCA1 
immunoprecipitates (121); therefore, the localization of ABCA1 was compared to that of 
SPT1 in HEK293 cells (Fig. 3.10). Most of the ABCA1 staining appeared to be 
associated with intracellular membranes (and in a pattern similar to that for SPT1), and a 
portion (see expanded panel in the lower half of Fig. 3.10 and merge) was also detected 
in focal adhesion-like assemblies in the same vicinity as SPT1. These results are 
consistent with the proposal that SPT1 and ABCA1 interact (121), although it is not clear 
if this is direct or perhaps by binding to the same scaffold protein system, as will be 
discussed later.  
 
 
 
 
Fig. 3.10  Localization of SPT1 and ABCA1 in HEK cells.  
HEK293 cells grown on collagen coated coverslips were stained with rabbit anti-
SPT1 antibody and mouse anti-ABCA1 antibody followed by Alexa Fluor 488 anti-
rabbit antibody (green) and Alexa Flour 568 anti-mouse antibody (red). The 
enlarged images show the localization similarity of the two proteins at the leading 
edge of the cell. Upper panel: bar, 10 µm; lower panel: bar, 5 µm. 
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3.3.8 Unlike native SPT1, overexpressed SPT1s do not localize in the nucleus nor 
focal adhesions 
As has been seen before with HA-tagged SPT1 in LY-B cells (18), immunostaining of 
SPT1 in SPT1-overexpressing HEK cells appears to detect SPT1 only in the ER (Fig. 
3.1A).  This was also seen with SPT1 constructs with other types of epitope tags, 
including both N- (pEGFP-C2-SPTLC1) and C-terminal (pEGFP-N1-SPTLC1) GFP-
tagged SPT1s (Fig. 3.11A), SPT1 constructs with a smaller amino-terminal MAT-FLAG 
tag and a carboxyl-terminal HA tag (Fig. 3.11B, which shows the combined construct 
with detection using an anti-HA antibody, but the individual constructs gave similar 
results), and an SPT1 recombinant with three HA tags between amino acids 97 and 98 
(Fig. 3.11B, lower), which is in a region of the SPT1 polypeptide that is likely to be an 
external loop based on proposed three-dimensional structures (131, 132) (this construct 
was made in case an N- or C- terminal tag interferes with the localization of SPT1 in the 
nucleus and focal adhesions). 
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3.4 Discussion 
 
Serine palmitoyltransferase has been long thought to reside in the ER where de novo 
sphingolipid biosynthesis is initiated (115), and these studies have confirmed that at least 
a portion of the endogenous SPT1, and essentially all of the ectopically expressed SPT1s, 
have this localization.  The more novel contributions of these studies are:  i) the 
establishment that a portion of the endogenous SPT1 is also located in the nucleus and 
focal adhesions, as had been suggested but not proven earlier (98, 119, 120); and ii) the 
Fig. 3.11 Localization of N-, C- and internally tagged SPT1 in HeLa cells.  
(A) Hela cells were grown on collagen coated coverslips, transfected with pEGFP-N1-
SPT1 or pEGFP-C2-SPT1 for 24 h, and then fixed for confocal imaging.  (B) HeLa cells 
were transfected with pCMV MAT FLAG-SPTLC1-HA or pcDNA-SPTLC1-internal HA 
before immunofluorescence staining using an anti-HA antibody. Bar, 10 µm.  
 
 80 
demonstration that the localization in focal adhesions is related to, and apparently 
necessary for, cell migration and maintenance of a normal cell morphology.  
  
The structural basis for the surprising localization of SPT1 with the nucleus and focal 
adhesions is not known, however, SPT1 is predicted to have multiple PDZ binding motifs 
(e.g., a Class II motif at AVLL470-473, and four Class III domains binding motifs at 
VEMV11-14, KEEL57-60, EELI58-61 and PEPL66-69) using the ELM (Eukaryotic Linear 
Motif) functional site prediction tool (http://elm.eu.org/) (133) and the UniProtKB/Swiss-
Prot identifier for human SPTLC1: O15269.  These motifs might interact with PDZ-
containing scaffold proteins in the nucleus and plasma membrane because PDZ-
containing scaffold proteins are known to assemble multiprotein complexes in such 
locations to perform specialized local functions such as organization of subcellular 
structures and signal transduction (134, 135).   
 
Additional evidence for the possibility of such interactions has been provided by the 
recent report (121) that SPT1 is associated with ABCA1, and our confirmation that at 
least a portion of both are in the vicinity of focal adhesions (Fig. 3.9). ABCA1 is thought 
to interact with β-syntrophin/utrophin complexes through syntrophin PDZ domains (136, 
137), which could also account for the SPT1 (and ABCA1) in focal adhesions via the 
binding of utrophin to the actin cytoskeleton and the dystroglycan complex in the plasma 
membrane (138, 139).  The reported interaction of ABCA1 and SPT1 (121) might, 
therefore, be indirect and mediated by a mutual interaction with β-syntrophin or another 
protein with multiple PDZ domains.  
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The physiologic significance of this interaction is not known, but might provide a 
mechanism to link sphingolipid metabolism and S1P delivery and/or removal from the 
cell because ABCA1 is the major receptor for HDL (140), the major plasma carriers of 
S1P (141).  S1P can inhibit de novo sphingolipid biosynthesis (74), therefore, perhaps the 
SPT1 in these atypical localizations is serving as a “sphingoid base status sensor” rather 
than as a subunit of the catalytically active SPT1-SPT2 dimer (17) or multimer (19). It is 
interesting that HDL also promote endothelial cell motility (142).  The finding that SPT1 
is associated with focal adhesions at the migrating edge of cells in the scratch-wound 
healing assay (Figure 3.8), and that knockdown of SPT1 mRNA caused cell rounding 
(Figure 3.5 and 3.6) would be consistent with a role for SPT1 in cell adhesion and 
migration.   
 
The nuclear localization of SPT1 might also be a consequence of interactions with 
scaffold proteins such as gamma 1-syntrophin that have PDZ motifs and participate in the 
translocation of other proteins (e.g., DGK-zeta) (143) between the cytoplasm and nucleus.  
Many focal adhesion proteins have been found in the nucleus, and play a role in signaling 
from focal adhesion to nucleus (144). In addition, SPT1 has a transcription cofactor motif 
(LXXLL) that is found in coregulators that shuttle between nucleus and cytoplasm.  
Considering that new transcriptional coregulators are continually being discovered and 
these include factors that were not expected to serve such functions (145) and even 
nuclear receptors that are down-regulated by binding sphingosine (146), these 
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possibilities should be borne in mind as a potential explanation for the nuclear 
localization of SPT1.  
 
The finding that all of the SPT1 constructs prepared by us and others (18) produce a 
recombinant protein that appears only in the ER and not in the nucleus and focal 
adhesions complicates follow-up investigations into these hypotheses (such as by deletion 
of the PDZ-binding motifs to determine how this affects localization).  There is currently 
no explanation for this distinction, but it is not unprecedented because neutral 
sphingomyelinase (nSMase1), for example, has also been found in the nucleus of cells, 
but the over-expressed enzyme does not appear there (147).  Such behavior might be 
caused by the existence of additional, endogenous isoform(s), such as splice variants, or 
perhaps co- or post-translational modification(s) that is (are) important for protein folding 
and/or interaction with binding partners.  These are important questions for future study. 
 
3.5 Conclusions 
 
SPT1 was found not only in ER but also in the nucleus and focal adhesions using 
immunofluorescence confocal microscopy.  
 
SPT1 co-localizes and interacts with a focal adhesion marker protein, vinculin. 
 
siRNA silencing of SPTLC1 but not SPTLC2 caused cell morphology change and this 
phenomenon was not related to the intracellular sphingolipid change. 
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SPT1 focal adhesion staining disappeared when the cells reached confluence and 
appeared in migrating cells.  
 
SPT1 colocalized with ABCA1, a lipid transporter to form HDL particles, at focal 
adhesion like structures.  
 
Overexpressed SPT1 did not get to the nucleus or focal adhesions. 
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CHAPTER 4 
 
Investigations on SPTLC1 isoforms 
 
4.1 Introduction  
 
Although all of the studies to date of SPT1 have focused on one transcript, three SPTLC1 
mRNA isoforms are found in the GenBank database.  The functions of these isoforms are 
not yet known, but they might be responsible for biosynthesis of different types of 
sphingoid bases.  The prevalence of sphingoid bases with 18-carbons in most 
sphingolipids is thought to be due to the specificity of SPT for the co-substrate fatty acyl-
CoA, with the mammalian enzyme (17, 31) utilizing palmitoyl-CoA (C16:0) > 
pentadecanoyl- and heptadecanoyl- CoA’s (C15:0 and C17:0) >> stearoyl-CoA (C18:0).  
However, other chain length sphingoid bases (with 20-carbon atoms) are found in 
mammalian brain gangliosides (1), and have been selectively localized in hippocampus 
by imaging mass spectrometry analysis (38).  Therefore, it is possible that one of the 
alternative SPT1 isoforms may be responsible for producing such species.  To explore 
this possibility, the isoform (SPTLC1L) originally found in hippocampus was isolated and 
expressed in LYB cells to explore if it is functional and responsible for the synthesis of 
sphingolipids with a C20-sphingoid base.   
 
4.2 Materials and methods  
 
 
4.2.1 Materials 
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The SPTLC1L plasmid pcDNA used in this study was cloned by Dr.Leipelt. SPT1L 
specific antibody targeting to the C-terminal of the protein was provided by Dr.Ulinger. 
The epitopes used for immunization are “PRGRTGESC” and “PPATQHAERTQDSR”. 
LYB cells, mutant CHO cells which do not have SPT activity due to SPT1 deficiency, 
were provided by Dr. Hanada (Japan). 
 
4.2.2 Cell culture  
 
LYB cells were grown in F12 medium (Gibco) with 10% fetal bovine serum. The cell 
culture condition was the same as described in Chapter 2. 
 
4.2.3 Western blotting  
 
Western blotting was performed as described in Chapter 3. 
 
4.2.4 Transfection of LYB cells 
 
The transfection was performed according to GeneJuice transfection protocol as 
described in Chapter 3. The day before transfection, 8 × 10
5 
cells were seeded in 
complete growth medium in 60-mm dishes. 5 µg DNA was added to each dish. 
  
4.2.5 In situ SPT activity assay 
 86 
 
This method has been described in Chapter 2. LYB cells were transfected with DNA 
plasmids for 24 hours and then incubated with 0.1 µM of [
13
C]-palmitate for 18 hours 
before collected for lipid extraction and ESI-MS/MS analysis.  
 
4.3 Results and Discussion 
 
4.3.1 Identification of mRNA isoforms of SPTLC1 in GenBank database 
 
Recent estimates suggest that about 40~60% pre-mRNAs are subject to alternative 
splicing, which accounts for proteome diversity under various situations (148, 149). 
Table 4.1 lists the three human SPT1 transcripts that are found in GenBank. The first one, 
as well as its homologs in mouse and hamster, has been studied previously (17-19, 24)  
and is thought to be responsible for functional SPT1 protein. The functions of the other 
two transcripts, if any, have not been reported, so far. They have very high similarity 
(96.9% and 31.3%) to SPTLC1 and the 5’ sequences of the three transcripts are identical. 
The second transcript (SPTLC1S) encodes a shorter peptide (16 kDa), while the third 
encodes a longer peptide (57 kDa), so we refer to it as SPTLC1L. The mRNA sequences 
of SPTLC1 and SPTLC1L are  identical except that the former one has an extra 32 bp in 
the middle. 
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Our abbreviation SPTLC1 SPTLC1S SPTLC1L 
mRNA name from 
GenBank 
Homo sapiens serine 
palmitoyltransferase, 
long chain base 
subunit 1 (SPTLC1), 
transcript variant 1. 
Homo sapiens serine 
palmitoyltransferase, 
long chain base 
subunit 1 (SPTLC1), 
transcript variant 2. 
Homo sapiens serine 
palmitoyltransferase, 
long chain base 
subunit 1. 
GenBank No. NM006415 NM178324 BC068537 
Length (bp) 2780  998  2742  
Encoding protein 
size (kDa) 
53  16  57  
 
 
 
4.3.2 Genomic DNA sequence analysis suggests that the SPTLC1L and SPTLC1S 
mRNA were generated through alternative splicing 
 
The SPTLC1 gene contains 15 exons. By analyzing SPTLC1 isoform cDNA sequences 
and SPTLC1 genomic DNA sequence, we noticed that both SPTLC1 isoforms were likely 
to arise from alternative splicing.  
 
In the case of SPTLC1L, the first 32 nucleotides of exon 15 are missing, therefore, this 
deletion causes a frame shift which bypasses the original stop codon and makes a stop 
codon 149 nucleotides downstream (Fig. 4.1). Since in most cases alternative spliced 
sequences are longer than 50 nucleotides (150), is this short alternative splicing possible?  
Apparently so because there has been a recent report of very short alternative splicing (< 
50 nucleotides), and it has been proposed that such might contribute more to protein-
function diversity than has been previously thought (150). Splicing consensus sequences 
invariantly have GT at the start of the intron and AG at its end (151) and the SPTLC1 
Table 4.1 mRNA isoforms of human SPTLC1 
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gene has GT at the beginning of the intron between exon 14 and 15, and AG is not only 
found at the end of the intron but also at the end of the spliced sequence (Fig. 4.1). Thus, 
instead of proposing that the 32 nucleotides at the beginning of exon 15 have been 
spliced out to produce SPTLC1L, this might be due to 32 nucleotides of the intron being 
added to the beginning of exon 15 in SPTLC1.  
 
 
 
 
 
In the case of SPTLC1S, the mRNA would be generated by adding part of the intron 
between exon 5 and exon 6 to the end of exon 5, which generates a premature stop codon 
“TGA” right after exon 5 and, thus, only contains the first five exons of SPTLC1 gene(Fig. 
4.2). Translation of SPTLC1S would produce such a short peptide (16 kDa) that it would 
seem unlikely to have enzyme activity. However, this alternative splicing might act as a 
control mechanism adjusting SPTLC1 expression at mRNA level. 
 
 
 
TACAGTGCAT GAACAGAAGT ATTGCATTAA CTCAGGCGCG CTACTTGGAG 
AAAGAAGAGA AGTGTCTCCC TCCTCCCAGG TCAGTTGACG ………………………… 
………………………… ATAATTCTTT GTGTCCTTTA CTGTTCTCAG CATTCGGGTT 
GTGGTCACGG TGGAACAAAC AGAGGAAGAA CTGGAGAGAG CTGCGTCCAC 
CATCAAGGAG GTAGCCCAGG CCGTCCTGCT CTAGGCAGAG TCCCGGGACC 
ATGGCCTCCT GCCACACAAC ACGCAGAGAG GACTCAAGAC TCCCGCTGGC 
CATGGAGTGG CCTGAAAGAG AGCAAGAACA TGTGGATCTT TGATAGGATT 
GTTACCAAAT GGTGTCAGTA TGGACCAATT GTGTGACCAT ………………………… 
 
Fig. 4.1 SPTLC1 genomic sequence where alternative splicing of SPTLC1L happens 
The sequence contains exon 14 (black letters), an intron between exon 14 and 15 (grey 
letters) and part of exon 15 (black letters). The alternatively spliced sequence has an 
underline in it. The “TAG” stop codon for SPTLC1 and “TGA” stop codon for SPTLC1L 
are in bold letters.   
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We elected to express the longer form, SPTLC1L, because its similarity to SPTLC1 in 
sequence and size makes it likely that it will be able to form a dimer with the other SPT 
subunits (SPT2 or SPT3) for catalytic activity, and--since it was first identified from 
brain tissue which is the same place where C20 sphingoid bases were found –perhaps the 
SPTLC1L-SPT2 heterodimer is responsible for the synthesis of C20 sphingolipids.   
 
4.3.3 The endogenous SPT1L protein was detected by Western blotting 
 
Since the SPTLC1c mRNA sequence is almost identical to SPTLC1 (only lacking the 32 
nucleotides in the middle of the sequence), it is difficult to identify this transcript by PCR. 
However, the frame shift caused by alternative splicing should result in an amino acid 
TTCAATAAAG GCAGCAGCTT TAGCATCTCT AAAGAAGTAT GGCGTGGGGA 
CTTGTGGACC CAGAGGATTT TATGGCACAT TTGGTAAGTT ………………………… 
TTATCTTTCT AGAATGAAGA TGAAGGATCA TTGATTTCCT TGTGTATGGA 
TAATCCGGGA ACAGGCCAAC TAAATATTTG ATGAATGTAT GATTTCAAAT 
ACAGTGAATT CCCTGGGAGT CATCAAAGAA GACCGGCATT TTATGGTTGT 
TTTTATTAAG TGTATATTCT TTGCTCCTGA AAATGTTATT AAATAATTGT 
TTAGGCCGGG CATGGTGGCT CATGCCTGTA ATCCCAGCAC TTTCAAAGGC 
TGAGGCAGGC AGATCACCTG AGGTCAGGAG TTCAAAACCA GCCTGGCCAA 
CATGCTGAAA CCTCGTCTCT ACTAAAAATA CAAAAATTAG CTGGGCGTGG 
TGGTGGATAC CTGTAATCCC AGCTACGTGG GAGGCTGAGG TGGGAGAATT 
GCTTCAACCT GGGAGGCAGA GGTTGCAGTG AGCCGAGATC ATGCCACTGC 
ACTCCAGCCT GGGCAACAGA GCAAGACTGT CTCAAAAATA AATAAATAAA 
TAAAATTGTT TAAATGAATT TATTGCTGGA AATAGCATTT ………………………… 
 
Fig. 4.2 SPTLC1 genomic sequence where alternative splicing of SPTLC1S happens  
The sequence contains exon 5 (black letters) and an intron between exon 5 and exon 6 
(grey letters). Part of this intron (underlined sequence) is added at the end of exon 5, 
which generates a premature stop codon “TGA” (bold letters) right after exon 5. This 
splicing produces SPTLC1S which only contains the first five exons of SPTLC1 gene. 
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sequence of the isoform that has a unique c-terminal. An anti-SPT1L antibody was 
generated targeting to this unique sequence [[did you give the sequence?  maybe but I 
don’t recall.  if not put it here]]] and used for Western blotting of a HEK293 cell lysate 
(Fig. 4.3).  This found that the antibody detects a band slightly above the 55 kDa marker, 
which is consistent with the predicted molecular weight of SPT1L.  
 
 
 
 
 
4.3.4 SPT enzyme activity assay of LYB cells transfected with SPTLC1L using [
13
C]-
palmitate as a substrate  
 
To test if the SPTLC1L isoform has enzyme activity, it was expressed in LYB cells 
because LYB cells do not have SPT enzyme activity due to SPT1 deficiency and provide 
a useful model. LYB cells were transfected with pcDNA-SPTLC1L or pcDNA-SPTLC1 
for 24 hours and then incubated overnight in medium containing 0.1 mM [
13
C]-palmitate 
(it is possible to use stable-isotope-labeled palmitic acid rather than stearic acid because 
our lab has found that palmitoyl-CoA can be elongated to stearyl-CoA, so labeled stearyl-
CoA is available inside the cells). The cells were collected for lipid extraction and LC 
ESI-MS/MS analysis, but the studies did not detect any incorporation of 
13
C into either 
55 kD 
Fig. 4.3 Western blotting of HEK293T cell lysate with anti-SPT1L antibody  
30 ug of total cell lysate from HEK293t cells were applied for SDS-PAGE followed by 
Western blotting using anti-SPT1L antibody. 
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C18- or C20-sphingoid bases.  To determine if this might be due to an incompatibility 
between the human SPTLC1L and hamster SPTLC2, SPTLC1L and human SPTLC2 were 
co-transfected, but this did result in the production of 
13
C-labelled sphingolpids.  
Therefore, it is unclear what the function of this isoform is. 
 
4.4 Possible directions for future research 
 
The lack of SPT activity when SPTLC1L was transfected into LYB cells does not prove 
that this polypeptide does not function as an SPT subunit.  We might not have choosen 
the right cell line for these studies, and a brain tissue derived cell line might be more 
successful. It is also possible that the function of SPT1L might require partners and co-
transfection of them might be required for SPT activity. Lastly, it is also possible that 
SPT1L might play a role other than synthesis of sphingolipids, which would be a more 
difficult outcome to study.   
 
4.5 Conclusions 
 
SPTLC1L and SPTLC1S sequences were identified as alternative spliced mRNA isoforms 
of SPTLC1. 
 
The existence of SPT1L peptide in HEK293 cells was confirmed by western blotting 
using a specific antibody. 
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Transfection of SPTLC1L into LYB cells did not rescue the cells in SPT activity, but the 
possibility that the SPT1L may have an enzymatic function warrants further study.  
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OVERALL CONCLUSIONS 
 
Sphingolipid biosynthesis is one of the most complex metabolic processes of mammalian 
cells, involving hundreds of enzymes, multiple pathways for intra- and extra-cellular 
trafficking and transport, and dozens (at least) of associated biological functions that are 
regulated by the types and amounts of sphingolipids that are present.  Nonetheless, very 
little is known on a biochemical level about even the first few steps of the de novo 
sphingolipid biosynthetic pathway. How many polypeptides are involved?  Where are 
they located? What are their functions? What are the consequences of changing their 
amounts or types? Etc. Therefore, the goal of this thesis was to explore some of these 
fundamental questions by an overall study of SPT, the first and key enzyme in this 
pathway, at a gene expression level, a protein level and an in situ enzyme activity level.  
 
We found that SPT1 protein was not only in the ER but also in focal adhesions and the 
nucleus using immunofluorescence confocal microscopy. SPT1 co-localizes and interacts 
with a focal adhesion marker protein, vinculin. The siRNA silencing of SPTLC1 but not 
SPTLC2 caused cell morphology changes, and this phenomenon does not appear to be 
related to sphingolipid changes. Furthermore, SPT1 focal adhesion staining disappeared 
when the cells reached confluence and appeared in migrating cells. It also colocalized 
with ABCA1, a lipid transporter to form HDL particles, at focal adhesion like structures. 
Therefore, our results suggest a role of SPT1 in processes beyond just initiation of de 
novo sphingolipid biosynthesis, including cell morphology and cell migration.  
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Our interpretation of the sequences of the SPTLC1 mRNA isoforms in GenBank suggests 
that they were generated by alternative splicing, and the endogenous expression of at 
least one, SPTLC1L, in HEK293 cells by Western blotting confirms this prediction. The 
functions of such isoforms are not yet clear, but they may help explain differences in 
subcellular localization, regulation or other aspects of sphingolipid biology. 
 
Overexpression of SPTLC1 and SPTLC2 in HEK293 cells (SPT1/2 cells) elevated SPT 
enzyme activity. The dynamics of de novo synthesis of sphingolipids was measured in 
both HEK293 cells and SPT1/2 cells after cells were incubated with [
13
C]-palmitate. The 
de novo synthesized sphingolipids increased more rapidly in SPT1/2 cells than in 
HEK293 cells except for SM. Sphingolipid subspecies with different fatty acyl-chains 
were compared in the two cell types and C18 subspecies had the highest fold elevation in 
SPT1/2 cells. That SM did not increase to the same extent in SPT1/2 cells does not 
appear to be due to increased SM degradation, but rather, appears to be due to a change in 
the substrate pool—i.e., elevation of dihydroceramidse. The elevated SPT activity by its 
stable overexpression evidently increased the flux through the pathway and the amounts 
of up-stream molecules to the such a high degree that it exceeded the capacity of the 
down-stream enzymes, such as dihydroceramide desaturase, to accommodate them, thus 
slowing down the relative production of some of the later products of the pathway. 
  
The finding of elevated amounts of two novel sphingoid base species, the 1-deoxy-
sphingoids, in SPT1/2 cells suggests that SPT uses not only serine but also alanine and 
glycine as its substrate to synthesize these sphingolipids. 
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Also, it was of interest that overexpression of SPT caused accumulation of cytotoxic 
sphingolipids (ceramides as well as sphingoid bases) but the cells did not die and instead 
grow faster. It has been known that sphingolipids participate in various biological 
responses such as stress response, cell cycle arrest and apoptosis etc. (3) and some 
chemotherapy drugs, like etoposide and doxorubicin (70, 152), act through increasing 
intracellular ceramide. Our study of SPT activity in situ using [
13
C]-palmitate labeling 
allowed us to follow the flux through the pathway, and to find that ceramide elevation 
can occur without cell killing. Therefore, the elevation of ceramide in cases where it is 
cytotoxic apparently reflects that it is necessary for cell death, but not necessarily 
sufficient alone.  
  
Our studies of SPT have revealed that the complexity of this protein is much greater than 
has been previously appreciated. Not only its classic sphingolipid biosynthesis function 
was further investigated but also its novel function at novel locations was explored. Our 
finding of SPT1 in the nucleus and focal adhesions implicate it in cell morphology, 
migration and signaling. Glycosphingolipids and S1P have been found to be involved in 
focal adhesion and cell migration (4, 12), but this is the first report that a sphingolipid 
synthesis enzyme plays a direct role in the processes. SPT1 may become a new model in 
the family of multi-functioning proteins and provide a clue of regulation of sphingolipid 
synthesis. More studies are needed to elucidate the molecular structure and connections 
of SPT1 in these locations.  
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Future studies should also measure the impact of SPT overexpression on more complex 
GSL. Analyzing these molecules will be a heavy task, requiring high throughput MS 
methods and efficient data analysis tools. But once the methods are developed, the de 
novo synthesis of sphingolipids can also be explored in different biological systems. For 
example, the stem cells would be an interesting object to study because complete 
knockout of SPTLC1 or SPTLC2 is lethal for embryos (87) though sphingolipids can be 
taken from the serum. And, point mutations of SPTLC1 cause HSN1 disease, and there 
may be others that have not yet been found (and it would be interesting to know if the 
mutations in HSN1 patients affect SPT1 novel functions which we found in this study). 
Obviously, more work is required to define the mechanisms of regulation of the enzyme 
and roles of the pathway in specific biological systems. 
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APPENDIX  
Quantification of sphingolipids in HEK293 and SPT1/2 cells after [
13
C]-
palmitate treatment 
 
 
 
 
 
 
 
 
Fig. A.1 Ceramide analysis in HEK293 cells treated with 0.1 mM [
13
C]-palmitate 
HEK293 cells were incubated in the complete growth medium containing 0.1 mM 
13
C-palmitate for 0 to 6 hours. Cells were collected every hour for lipid extraction. 
Then the samples were analyzed by HPLC and ESI-MS/MS. Ceramide molecules 
with various fatty acyl chain lengths were quantified. 
13
C dual labeling (up left), base 
labeling (up right), fatty acid labeling (bottom left) and unlabeled ceramide (bottom 
right) are presented in the figure.        
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Fig. A.2 DHCer analysis in HEK293 cells treated with 0.1 mM [
13
C]-palmitate 
Same treatment was done as described above. 
13
C dual labeling (up left), base labeling 
(up right), fatty acid labeling (bottom left) and unlabeled dihydroceramide (bottom 
right) are presented in the figure. 
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Fig. A.3 CMH analysis in HEK293 cells treated with 0.1 mM [
13
C]-palmitate 
Same treatment was done as above. 
13
C dual labeling (up left), base labeling (up right), 
fatty acid labeling (bottom left) and unlabeled CMH (bottom right) are presented in 
the figure.        
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Fig. A.4 DHCMH analysis in HEK293 cells treated with 0.1 mM [
13
C]-
palmitate  
Same treatment was done as above. 
13
C dual labeling (up left), base labeling (up 
right), fatty acid labeling (bottom left) and unlabeled DHCMH (bottom right) are 
presented in the figure.        
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Fig. A.5 SM analysis in HEK293 cells treated with 0.1 mM [
13
C]-palmitate  
Same treatment was done as above. 
13
C dual labeling (up left), base labeling (up 
right), fatty acid labeling (bottom left) and unlabeled SM (bottom right) are presented 
in the figure.     
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Fig. A.6 DHSM analysis in HEK293 cells treated with 0.1 mM [
13
C]-palmitate 
Same treatment was done as above. 
13
C dual labeling (up left), base labeling (up 
right), fatty acid labeling (bottom left) and unlabeled dihydrosphingomyelin 
(bottom right) are presented in the figure.     
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Fig. A.7 Cer analysis in SPT1/2 cells treated with 0.1 mM [
13
C]-palmitate  
Same treatment was done as above in SPT1/2 cells. 
13
C dual labeling (up left), base 
labeling (up right), fatty acid labeling (bottom left) and unlabeled ceramide (bottom 
right) are presented in the figure.   
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Fig. A.8 DHCer analysis in SPT1/2 cells treated with 0.1 mM [
13
C]-palmitate 
Same treatment was done as above in SPT1/2 cells. 
13
C dual labeling (up left), base 
labeling (up right), fatty acid labeling (bottom left) and unlabeled dihydroceramide 
(bottom right) are presented in the figure.      
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Fig. A.9 CMH analysis in SPT1/2 cells treated with 0.1 mM [
13
C]-palmitate  
Same treatment was done as above in SPT1/2 cells. 
13
C dual labeling (up left), base 
labeling (up right), fatty acid labeling (bottom left) and unlabeled ceramide 
monohexocide (bottom right) are presented in the figure. 
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Fig. A.10 DHCMH analysis in SPT1/2 cells treated with 0.1 mM [
13
C]-palmitate 
Same treatment was done as above in SPT1/2 cells. 
13
C dual labeling (up left), base 
labeling (up right), fatty acid labeling (bottom left) and unlabeled dihydroceramide 
monohexocide (bottom right) are presented in the figure.      
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Fig. A.11 SM analysis in SPT1/2 cells treated with 0.1 mM [
13
C]-palmitate  
Same treatment was done as above in SPT1/2 cells. 
13
C dual labeling (up left), base 
labeling (up right), fatty acid labeling (bottom left) and unlabeled sphingomyelin 
(bottom right) are presented in the figure.     
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Fig. A.12 DHSM analysis in SPT1/2 cells treated with 0.1 mM [
13
C]-palmitate 
Same treatment was done as above in SPT1/2 cells. 
13
C dual labeling (up left), base 
labeling (up right), fatty acid labeling (bottom left) and unlabeled 
dihydrosphingomyelin (bottom right) are presented in the figure.       
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